Author Index to Volume 42

Abraham G. See Verghese C
Abraham JT, Brown R, Meltzer HY. Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use, 144
Adair JC. See Escalona PR
Adityanjee. See Lindenmayer J-P
Adler CM. See Malhotra AK
Adolfsson R. See Engström C
Adrien J-L. See Roux S
Ahern GL. See Lane RD
Ahmed SK. See Ng Ying Kin NMK
Aitchison KJ. See Kunugi H
Akiyoshi J, Isogawa K, Tsutsumi T, Kasturagi S, Kohno K, Furuta M, Yamamoto Y, Yamada K, Fujii I. Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia, 151
Alim T. See George DT
Alpert JE. See Fava M
Alpert NM. See Rauch SL
Altamura C. See Maes M
Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman self-rating mania scale, 948
Altsteil L. See Powchik P
Aluoja A. See Shlik J
Amin M. See Ng Ying Kin NMK
Anderson JL. See Vasile RG
Andreasen NC. See Torres IJ
Ansseau M. See Hansenne M
Antkiewicz-Michaluk L, Krygowska-Wajs A, Szczudlik A, Romańska I, Vetulani J. Increase in sasolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology, 514
Antonelli T. See Ferraro L
Arancio C. See Brambilla F
Arnold SE, Ruscheinsky DD, Han L-Y. Further evidence of abnormal cytoarchitecture of the entorhinal cortex in schizophrenia using spatial point pattern analyses, 639
Arolt V, See Rothermundt M
Arranz MJ. See Kunugi H
Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo, 233
Asarnow RF. See Strandburg RJ
Asghari V. See Young LT
Åström M. See Engström C
Atsumi Y. See Miyaoka H
Ault K. See Friedman J
Avraham S. See Spivak B
Azzoni A. See Daniele A

Badan M. See Curtin F
Badawy AA-B. See Mokhtar ASE
Baer L. See O'Sullivan RL
Baker DG. See Kellner M
Balant L. See García-Sevilla JA
Ball D. See Kunugi H
Bark N. See Lindenmayer J-P
Barthélémy C. See Roux S
Bartko JJ. See Ross DE
Basun H. See Forsell YA
Baxter LR Jr. See Szuba MP
Begleiter H
See Cohen HL
See Zhang XL
Begley AE. See Reynolds CF
Bellodi L
See Brambilla F
See Mundo E
See Perna G
Benatov R. See Rotenberg VS
Bensch C. See Morault PM
Bernstein D. See Intrator JT
Bertani A
See Brambilla F
See Perna G
Bianchi G. See Mundo E
Bieliauskas LA. See Jönsson EG
Biggins CA, MacKay S, Clark W, Fein G, Event-related potential evidence for frontal cortex effects of chronic cocaine dependence, 472
Birmaher B. See Kaufman J
Bizzi A. See Daniele A
Bjošrk A. See Svartangren J
Bleich A. See Spivak B
Boehle C. See Hajek M
Bonello CM. See Pillay SS
Bonnet KA. See Boutros NN
Bonnet-Brilhault F, Laurent C, Thibaut F, Campion D, Chavand O, Samolyk D, Martinez M, Petit M, Mallet J. Serotonin transporter gene polymorphism and schizophrenia: an association study, 634
Born J. See Wolf OT
Bortolotti F. See Monteleone P
Bottaro G. See Pavone L
Bourgeois M. See Morault PM
Boutros NN, Bonnet KA, Millana R, Liu J. A parametric study of the N40 auditory evoked response in rats, 1051
Bradley DM. See Mokhtar ASE
Bradwejn J. See Shlik J
Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation, 889
Brambilla F, Perna G, Bellodi L, Arancio C, Bertani A, Perini G, Carraro C, Gava F. Plasma interleukin 1β and tumor necrosis factor concentrations

© 1997 Society of Biological Psychiatry

0006-3223/97/$17.00
PII S0006-3223(97)00502-7

in obsessive-compulsive disorder, 976
Breier A. See Malhotra AK
Breiter HC. See O'Sullivan RL
Brett PM, Curtis D, Robertson MM, Gurling HMD. Neuroreceptor subunit genes and the genetic susceptibility to Gilles de la Tourette syndrome, 941
Brichtswein K. See Intrator J
Brodaty H. See Hickie I
Brown R. See Abraham JT
Brown RP. See Mann JJ
Brown S. See Roy M
Brown WS. See Strandburg RJ
Browne ST. See Gorman JM
Bruneau N. See Roux S
Brunner DP. See Reynolds CF III
Buchanan RW. See Ross DE
Buchsbaum M. See Raine A
Bush G. See Petrides G
Busquets X. See García-Sevilla JA
Butschky MF. See Pickworth WB
Buysse DJ
See Perlis ML
See Reynolds CF III

Campion D. See Bonnet-Brilhault F
Cannon TD. See Eyler Zorrilla LT
Cappiello A, Sernyak MJ, Malison RT, McDougle CJ, Heninger GR, Price LH. Effects of acute tryptophan depletion in lithium-remitted manic patients: a pilot study, 1076
Carraro C. See Brambilla F
Carson SW. See Ruegg RG
Casacchia M. See Stratta F
Castejon O. See Palmar M
Catapano F. See Monteleone P
Caviness VS. See O'Sullivan RT
Chang L, Mehringer CM, Ernst T, Melchor R, Myers H, Forney D, Satz P. Neurochemical alterations in asymptomatic abstinent cocaine users. A proton magnetic resonance study, 1104
Charles HC. See Tupler LA
Charney DS. See Stine SM
Chavand O. See Bonnet-Brilhault F
Chen J-S. See Mann JJ
Chen J-Y. See Lan T-H
Chen YR. See Johnson BA
Claffey E. See Craddock N
Clark W. See Biggins CA
Claypoole K. See Radant AD
Clyde C. See Johnson BA
Coakley D. See Swanwick GRJ
Coccaro EF, Kavoussi RJ, Hauger RL. Serotonin function and antiaggressive response to fluoxetine: a pilot study, 546
Coen RF. See Swanwick GRJ
Cohen HL, Porjesz B, Begleiter H, Wang W. Neuroelectric correlates of response production and inhibition in individuals at risk to develop alcoholism, 57
Coleman M. See Pavone L
Collier DA. See Kunugi H
Colombo G. See Perna G
Conacher GN. Social dominance as a confounding factor in studies of primate aggression and serotonin, 305-corr
Condray R. See Steinhauer SR
Cook EH. See Unis AS
Cooney JM, Lucey JV, O'Keane V, Dinan TG. Specificity of the pyridostigmine/growth hormone challenge in the diagnosis of depression, 827
Coplan JD. See Gorman JM
Copolov D. See Marzella PL
Corder EH. See Forsell Y
Corrigan M. See Ruegg RG
Cowley DS. See Radant AD
Craddock N, McKeon P, Moorhead S, Guy C, Harrison D, Mynett-Johnson L, Claffey E, Feldman E, McGuffin P, Owen MJ, O'Donovan MC. Expanded CAG/CTG repeats in bipolar disorder: no correlation with phenotypic measures of illness severity, 876
Crowe RR. See Kato T
Cuesta MJ. See Peralta V
Curry T. See Martin CA
Curtin F, Walker J-P , Peyrin L, Soulier V, Badran M, Schulz P. Reward dependence is positively correlated to urinary monoamines in normal men, 275
Curtis D. See Brett PM

Dahl RE. See Kaufman J
Dahmen N, Fehr C, Reuss S, Hiemke C. Stimulation of immediate early gene expression by desipramine in rat brain, 317
Daneluzzo E. See Stratta P
Daniele A, Azzoni A, Bizzi A, Rossi A, Gainotti G, Mazza S. Sexual behavior and hemispheric laterality of the focus in patients with temporal lobe epilepsy, 617
Dansart P. See Roux S
Davidson JRT. See Tupler LA
Davidson M
See Powchik F
See Stern RG
Davidson RJ. See Henriaues JE
Davis JM. See Altman EG
Davis M
See Grillon C
See Walker DL
deB Frederick B, Satlin A, Yurgelun-Todd DA, Renshaw PF. In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes, 147
de Leon J. See Tracy JI
Demedts P. See Maes M
Demitrack MA. See Grunhaus L
den Boer JA. See van Vliet IM
Denney D. See Stevens JR
DePaulo JR
See Kato T
See MacKinnon DF
Desnyder R. See Maes M
Dew MA. See Reynolds CF III
Dinan TG. See Cooney JM
Divadeenam KM. See Petrides G
Dolu N, Süer C, Özesmi Ç, Keleştimur F, Eşel E. Electrodermal activity in nonmedicated hyperthyroid patients having nondepressive symptoms, 1024
Donald RA. See Inder WJ
Dorfman D. See Intrator J
Dougherty GG Jr. See Steinhauer SR
Drake CL. See Schwartz PJ
Drnovsek B. See Lehofer M
Dysken MW. See Kim SW

Eckardt MJ. See George DT
Edwards C. See McCracken JT
Egner S. See Lehofer M
Eiser A. See Grunhaus L
Ekstrom RD. See Ruegg RG
Elizur A. See Rotenberg VS
Elman I. See Malhotra AK
Engström C, Åström M, Nordqvist-Karlsson B, Adolfsson R, Nylander P-O. Relationship between prophylactic effect of lithium therapy and family history of affective disorders, 425
Ernst T. See Chang L
Escalona PR, Adair JC, Roberts BB, Graeber DA. Obsessive-compulsive disorder following bilateral globus pallidus infarction, 410
Escribá PV. See García-Sevilla JA

Eşel E. See Dolu N
Eyler Zorrilla LT, Cannon TD, Kronenberg S, Mednick SA, Schulsinger F, Parnas J, Praestholm J, Vestergaard A. Structural brain abnormalities in schizophrenia, 1080

Fant RV. See Pickworth WB
Faraone SV. See Seidman LJ
Faris PL, See Kim SW
Farre C. See Peralta V
Fava M. See Pillay SS
Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF. Major depressive subtypes and treatment response, 568
Fehm HL. See Wolf OT
Fehr C. See Dahmen N
Fein G. See Biggins CA
Feldman E. See Craddock N
Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert F, Fuxe K. Modafinil: an antinarcoleptic drug with a direct neurochemical profile to d-amphetamine and dopamine uptake blockers, 1181
Fifield WJ. See Sullivan PF
Finkel MS. See Laghrissi Thode F
Fischman AJ. See Rauch SL
FitzGerald M, Malone K, Li S, Suckow R, Mann JJ. Plasma tryptophan levels and prolactin response to fenfluramine in healthy volunteers, 416
Fiumara A. See Pavone L
Flashman LA. See Torres IJ
Forney D. See Chang L
Forsell Y, Corder EH, Basun H, Lannfelt L, Viitanen M, Winblad B. Depression and dementia in relation to apolipoprotein E polymorphism in a population sample age 75+, 898
Frampton C. See Inder WJ
Francis A. See Petrides G
Franke P. See Mann K
Freedman R. See Olincy A
Freudenreich O, Weiner RD, McEvoy JP. Clozapine- induced electroencephalogram changes as a function of clozapine serum levels, 132
Friedman D. See Kazmerski VA
Friedman J. See Powchik P
Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine, 522
Fujii I. See Akiyoshi J
Furuta M. See Akiyoshi J
Fuxe K. See Ferraro L

Gainotti G. See Daniele A
Gangadhar BN. See Naga Venkatesha Murthy PJ
Gänsicke M. See Mann K
Garber SS. See Verghese C
García-Sevilla JA, Walzer C, Busquets X, Escribá PV, Balant L, Guimón J. Density of guanine nucleotide-binding proteins in platelets of patients with major depression: increased abundance of the $G\alpha_{i2}$ subunit and down-regulation by antidepressant drug treatment, 704
Garreau B. See Roux S
Garvey MJ, Underwood K. Association of N-acetyl β-glucosaminidase levels with seriousness of suicide attempts, 286
Gava F. See Brambilla F
George DT, Lindquist T, Ragan PW, Alim T, Eckardt MJ, Linnoila M. Effect of alcoholism on the incidence of lactate-induced panic attacks, 992
Geracioti TD Jr, Loosen PT, Orth DN. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression, 165
Gil-Ad I. See Spivak B
Gilbertson MW, van Kammen DP. Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia, 585
Giles DE. See Perlis ML
Gill M. See Kunugi H
Gilmore J. See Ruegg RG
Gjerde DK. See Unis AS
Goetz RR. See Gorman JM
Goffman AL. See Pickworth WE
Golden RN. See Ruegg RG
Goldman MB. See Luchins DJ
Goldstein JM. See Seidman LJ
Gomot M. See Roux S
Gonzalez Moreno A. See Hansenne M
Good KP. See Martzke JS
Goodman J. See Ross DE
Goodman JM. See Seidman LJ
Gorelick DA, Rothman RB. Stimulant sensitization in humans, 230-corr
Górka Z. See Zyss T
Gorman JM, Browne ST, Papp LA, Martinez J, Welkowitz L, Coplan JD, Goetz RR, Kent J, Klein DF. Effect of antipanic treatment on response to carbon dioxide, 982
Grachev ID. See O'Sullivan RL
Graeber DA.. See Escalona PR
Greden JF. See Grunhaus L
Greenberg D. See Powchik P
Griffin WST. See Omori M
Grillon C, Pellowski M, Merikangas KR, Davis M. Darkness facilitates the acoustic startle reflex in humans, 453
Grochowski S. See Lindenmayer J-F
Grunhaus L, Shipley JE, Eiser A, Pande AC, Tandon R, Krahn DD, Demitrack MA, Remen A, Hirschmann S, Greden JF. Sleep-onset rapid eye movement after electroconvulsive therapy is more frequent in patients who respond less well to electroconvulsive therapy, 191
Guérin P. See Roux S
Guimón J. See García-Sevilla JA
Gupta N. See Malhotra S
Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study, 529
Gurling HMD. See Brett PM
Gustafsson L. Inadequate cortical feature maps: a neural circuit theory of autism, 1138
Guthrie D. See Strandburg RJ
Guy C. See Craddock N
Guze BM. See Szuba MP

Hadjez J. See Rotenberg VS
Hajek M, Huonker R, Boehle C, Volz H-P, Nowak H, Sauer H. Abnormalities of auditory evoked magnetic fields and structural changes in the left hemisphere of male schizophrenics—a magnetoencephalographic magnetic resonance imaging study, 609
Hall M. See Reynolds CF III
Halper JP. See Mann JJ
Han L-Y. See Arnold SE
Handelsman L. See Intrator J
Hanna C. See Stein MB
Hansenne M, Pitchot W, Gonzalez Moreno A, Reggers J, Machurot P-Y, Ansseau M. Harm avoidance dimension of the Tridimensional Personality Questionnaire and

serotonin 1A activity in depressed patients, 959
Hare R. See Intrator J
Haroutunian V. See Powchik P
Harper DN, Nisbet RH, Siegert RJ. Dietary gluten and learning to attend to redundant stimuli in rats, 1060
Harper R. See Strandburg RJ
Harpur T. See Intrator J
Harrison D. See Craddock N
Hartman BK. See Kim SW
Hauger RL. See Coccaro EF
Hedeker D. See Altman EG
Hellhammer DH. See Wolf OT
Heninger GR
See Cappiello A
See Stine SM
Henningfield JE. See Pickworth WB
Henriques JB, Davidson RJ. Brain electrical asymmetries during cognitive task performance in depressed and nondepressed subjects, 1039
Henteleff RA. See Sweet RA
Herman MM. See Katsetos CD
Hickie I, Scott E, Wilhelm K, Brodaty H. Subcortical hyperintensities on magnetic resonance imaging in patients with severe depresssion—a longitudinal evaluation, 367
Hiemke C. See Dahmen N
Higley JD, Linnoila M, Mehlman PT, Taub DM, Poland RE. Social dominance as a confounding factor in studies of primate aggression and serotonin, 306-corr (response)
Hildebrandt G. See Lehofer M
Hill C. See Marzella PL
Hill T. See Vasile RG
Hinze-Selch D, Mullington J, Orth A, Lauer CJ, Pollmächer T. Effects of clozapine on sleep: a longitudinal study, 260
Hirschmann S. See Grunhaus L
Hishikawa Y. See Masuda Y
Hoch CC. See Reynolds CF III
Hoda F. See Kunugi H
Hoehn-Saric R
See Lehofer M
See Liebmann PM
Holland DD. See Yang R-K
Holm P. See Ng Ying Kin NMKT
Holsboer F. See Wiedemann K
Hong C-L. See Lan T-H
Hong KS, Kim SP, Na DL, Kim JG, Suh Y-L, Kim SE, Kim J-W. Clinical and genetic analysis of a pedigree of a thirty-six-year-old familial Alzheimer's disease patient, 1172
Hoover KM. See Kim SW
Ho Pian KL. See van Vliet IM
Houck PR. See Reynolds CF III
Howard TS. See Hughes JR
Hughes JR, Howard TS. Nicotine and caffeine use as confounds in psychiatric studies, 1184
Huonker R. See Hajek M
Husain MM. See Omori M
Hyde TM. See Katsetos CD

Inagaki T, Ishino H, Seno H, Ohguni S, Tanaka J, Kato Y. Psychiatric symptoms in a patient with diabetes mellitus associated with point mutation in mitochondrial DNA: a case report, 1067
Inder WJ, Donald RA, Prickett TCR, Frampton C, Sullivan PF, Mulder RT, Joyce PR. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression, 744
Indurski P. See Rotenberg VS
Intrator J, Hare R, Stritzke P, Brichtswein K, Dorfman D, Harpur T, Bernstein D, Handelsman L, Schaefer C, Keilp J, Rosen J, Machac J. A brain imaging (single photon emission computerized tomography) study of semantic and affective processing in psychopaths, 96
Iragui VJ. See Olichney JM
Ishino H. See Inagaki T
Isogawa K. See Akiyoshi J

Jagoṁagi K. See Shlik J
Janakiramaiah N. See Naga Venkatesha Murthy PJ
Jatlow PI. See Stine SM
Javitt DC. See Winsberg BG
Jenike MA
See O'Sullivan RL
See Rauch SL
Jeste DV. See Olichney JM
Joffe RT. See Young LT
Johannesson T. See Jönsson EG
Johnson BA, Chen YR, Swann AC, Schmitz J, Lesser J, Ruiz P, Johnson P, Clyde C. Ritanserin in the treatment of cocaine dependence, 932
Johnson P. See Johnson BA
Johnson PC. See Laghrissi-Thode F
Jönsson EG, Mirsky AF, Johannesson T, Wahlstrostsc̈m J, Bieliauskas LA, van Kammen DP, Sedvall GC. No cytogenetical abnormalities in a set of schizophrenic quadruplets, 1186-corr
Josiassen RC
See Tracy JI
See Verghese C
Joyce JN. See Gurevich EV
Joyce PR
See Inder WJ
See Sullivan PF

Kamijima K. See Miyaoka H
Karson CN. See Omori M
Kasturagi S. See Akiyoshi J
Kaszniak AW. See Lane RD
Kato T, Stine OC, McMahon FJ, Crowe RR. Increased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder, 871
Kato T, Winokur G, McMahon FJ, DePaulo JR, Crowe RR. quantitative analysis of leukocyte mitochondrial DNA deletion in affective disorders, 311
Kato Y. See Inagaki T
Katona C. See Ng Ying Kin NMK
Katsetos CD, Hyde TM, Herman MM. Neuropathology of the cerebellum in schizophrenia–an update 1996 and future directions, 213
Kaufman J, Birmaher B, Perel J, Dahl RE, Moreci P, Nelson B, Wells W, Ryan ND. The corticotropin-releasing hormone challenge in depressed abused, depressed nonabused, and normal control children, 669
Kavoussi RJ. See Coccaro EF
Kayahara T. See Kitayama I
Kazmerski VA, Friedman D, Ritter W. Mismatch negativity during attend and ignore conditions in Alzheimer's disease, 382
Keck PE Jr. See Strakowski SM
Keilp J. See Intrator J
Keks N. See Marzella PL
Keleştimur F. See Dolu N
Kellner M, Baker DG, Yehuda R. Salivary cortisol in Operation Desert Storm returnees, 849
Kennedy DN. See O'Sullivan RL
Kennedy MA. See Sullivan PF
Kennison SD. See Malhotra AK
Kent J. See Gorman JM
Kern W. See Wolf OT

Keuthen NJ. See O'Sullivan RL
Kim JG. See Hong KS
Kim J-W. See Hong KS
Kim SE. See Hong KS
Kim SP. See Hong KS
Kim SW, Dysken MW, Kushner MG, Kuskowski MA, Hoover KM, Klein KW, Faris PL, Hartman BK. Phenomenological and pharamacological study of provoked obsessive/anxiety symptoms in obsessive compulsive disorder: a preliminary study, 969
Kimhi R. See Rotenberg VS
Kingisepp P-H. See Shlik J
Kirkpatrick B. See Ross DE
Kirov G. See Kunugi H
Kirschbaum C. See Wolf OT
Kitayama I, Yaga T, Kayahara T, Nakano K, Murase S, Otani M, Nomura J. Long-term stress degenerates, but imipramine regenerates, nonradrenergic axons in the rat cerebral cortex, 687
Klein DF. See Gorman JM
Klein KW. See Kim SW
Klein P, Oertel J. Depression associated with pontine vascular malformation, 519
Klitgaard N. See Ng Ying Kin NMK
Knight B. See Ruegg RG
Knott PJ. See Yang R-K
Koed K, Linnet K. The serotonin transporter messenger RNA level in rat brain is not regulated by antidepressants, 1177
Kohno K. See Akiyoshi J
Komoroski RA. See Omori M
Kopala LC. See Martzke JS
Koren D. See Seidman LJ
Kosten TR. See Stine SM
Köster B. See Wolf OT
Koverola C. See Stein MB
Kowalska M. See Zyss T
Koyama T. See Odagaki Y
Kragh-Sorensen P. See Ng Ying Kin NMK
Krahn DD. See. Grunhaus L
Krishnan KRR. See Tupler LA
Kronenberg S. See Eyler Zorrilla LT
Krygowska-Wajs A. See Antkiewicz-Michaluk L
Krystal JH. See Stine SM
Kumar Das M. See Malhotra S
Kunugi H, Vallada HP, Hoda F, Kirov G, Gill M, Aitchison KJ, Ball D, Arranz MJ, Murray RM, Collier DA. No evidence for an association of affective drugs with high or low-activity allele of catechol-*o*- methyl transferase gene, 282
Kupfer DJ
See Perlis ML
See Reynolds CF III
Kushner MG, See Kim SW
Kuskowski MA. See Kim SW
Kutas M. See Olichney JM

LaCasse L. See Raine A
Lafer B
See Pillay SS
See Vasile RG
Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and β-thromboglobulin plasma levels in depressed patients with ischemic heart disease, 290
Lahti AC. See Ross DE
Lam RW. See Yatham LN
Lan T-H, Hong C-L, Chen J-Y, Sim C-B. Apolipoprotein ϵ4 frequency in patients with schizophrenia, 225
Lane RD, Ahern GL, Schwartz GE, Kaszniak AW. Is alexithymia the emotional equivalent of blindsight?, 834
Lannfelt L. See Forsell Y
Larue S. See Martial J
Lasko NB. See Metzger LJ
Lauer CJ
See Hinze-Selch D
See Pollmächer T
Laurent C. See Bonnet-Brilhault F
Laville J. See Morault PM
Lawlor BA. See Swanwick GRJ
Lazeyras F. See Tupler LA
Leatherman ME. See Ruegg RG
Legl T. See Liebmann PM
Lehofer M, Moser M, Hoehn-Saric R, McLeod D, Liebmann P, Drnovsek B, Egner S, Hildebrandt G, Zapotoczky H-G. Major depression and cardiac autonomic control, 914
Lehover M. See Liebmann PM
Lesser J. See Johnson BA
Levitan I. See Verghese C
Leyton M. See Martial J
Li S. See FitzGerald M
Liberty V. See Schwartz PJ
Liebmann P. See Lehofer M
Liebmann PM, Lehofer M, Moser M, Hoehn-Saric R, Legl T, Pernhaupt G, Schauenstein K. Persistent analgesia in former opiate addicts is resistant to blockade of endogenous opioids, 962
Lindenmayer J-P, Adityanjee, Vital-Herne M, Bark N, Grochowski S, Moynihan N. Heterogeneity of serotonergic response in treatment-refractory schizophrenic patients, 6
Lindquist T. See George DT
Linnet K. See Koed K
Linnoila M
See George DT
See Higley JD
Litke A. See Zhang XL
Liu J. See Boutros NN
Lo KH. See Sweet RA
Lönnqvist J. See Partonen T
Loosen PT. See Geracioti TD Jr
Lucey JV. See Cooney JM
Luchins DJ, Nettles KW, Goldman MB. Anterior medial temporal lobe volumes in polydipsic schizophrenic patients with and without hypo-osmolemia: a pilot study, 767
Lutchmansingh P. See McCracken JT

MacDonald C. See Young LT
Machac J. See Intrator J
Machurot P-Y. See Hansenne M
MacKay S. See Biggins CA
MacKinnon DF, McMahon FJ, Simpson SG, McInnis MG, DePaulo JR. Panic disorder with familial bipolar disorder, 90
Maes M
Cytokines in obsessive-compulsive disorder, 1186- corr
Cytokines in schizophrenia, 308-corr
Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, Altamura C, Desnyder R. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness, 349
Mahowald MW. See Schenck CH
Maier W. See Mann KT
Mainous AG III. See Martin CA
Mainous RO. See Martin CA
Maj M. See Monteleone P
Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. Clozapine blunts *N*-methyl D-aspartate agonist-induced psychosis: a study with ketamine, 664
Malhotra S, Kumar Das M, Gupta N,

Muralidharam R. A Clinical study of Klein–Levin syndrome with evidence for hypothalamic-pituitary axis dysfunction, 299
Malison RT. See Cappiello A
Mallet J. See Bonnet-Brilhault F
Malone K. See FitzGerald M
Mancini F. See Stratta P
Manley P. See Mynett-Johnson LA
Mann JJ. See FitzGerald M
Mann JJ, Halper JP, Wilner PJ, Sweeney JA, Mieczkowski TA, Chen J-S, Stokes PE, Brown RP. Subsensitivity of adenylyl cyclase-coupled receptors on mononuclear leukocytes from drug-free inpatients with a major depressive episode, 859
Mann K, Maier W, Franke P, Röschke J, Gänsicke M. Intra- and interhemispheric electroencephalogram coherence in siblings discordant for schizophrenia and healthy volunteers, 655
Manzo PA. See O'Sullivan RL
Marcano A. See Palmar M
Marsden CA. See Mongeau R
Marsh JT. See Strandburg RJ
Martial J, Paris J, Leyton M, Zweig-Frank H, Schwartz G, Teboul E, Thavundayil J, Larue S, Ng Ying Kin NMK, Vasavan Nair NP. Neurendocrine study of serotonin function in female borderline personality disorder patients: a pilot study, 737
Martin CA, Mainous AG III, Mainous RO, Oler MJ, Curry T, Vore M. Progesterone and adolescent suicidality, 956
Martinez J. See Gorman JM
Martinez M. See Bonnet-Brilhault F
Martzke JS, Kopala LC, Good KP. Olfactory dysfunction in neuropsychiatric disorders: review and methodological considerations, 721
Marzella PL, Hill C, Keks N, Singh B, Copolov D. The binding of both [^{3}H]nemonapride and [^{3}H]raclopride is increased in schizophrenia, 648
Mason C. See Unis AS
Masuda Y, Ohnuma S, Shimizu T, Hishikawa Y. High sialic acid reactivity of sugar chain structure Lewis-XA in patients with mental retardation, 68
Matsuoka K. See Miyaoka H
Mattei P. See Stratta P
Matthews E. See Vasile RG
Mazumdar S
See Reynolds CF III
See Sweet RA
Mazza S. See Daniele A
Mazzone D. See Pavone L
McCann EM. See Tracy JI
McCracken JT, Poland RE, Lutchmansingh P, Edwards C. Sleep electroencephalographic abnormalities in adolescent depressives: effects of scopolamine, 577
McDougle CJ. See Cappiello A
Mc Evoy JP. See Freudenreich O
McGrory A. See Tracy JI
McGuffin P. See Craddock N
McInnis MG. See MacKinnon DF
McKeon P
See Craddock N
See Mynett-Johnson LA
McLeod D. See Lehofer M
McMahon FJ
See Kato T
See MacKinnon DF
Meador-Woodruff JH. See Ritter LM
Mednick SA. See Eyler Zorrilla LT
Medoff D. See Ross DE
Mehlman PT. See Higley JD
Mehringer CM. See Chang L
Melchor R. See Chang L
Meltzer HY
See Abraham JT
See Maes M
Mendlewicz J, Lindbald K, Souery D, Mahieu B, Nylander PO, De Bruyn A, Zander, Engström C, Adolfsson R, Van Broeckhover C, Shalling M, Lipp O. Expanded trinucleotide CAG repeats in families with bipolar disorder, 1115
Menninger JA, Tabakoff B. Forskolin-stimulated platelet adenylyl cyclase activity is lower in persons with major depression, 30
Merikangas KR. See Grillon C
Mester R. See Spivak B
Metzger LJ, Orr SP, Lasko NB, Pitman RK. Auditory event-related potentials to tone stimuli in combat related posttraumatic stress disorder, 1006
Mieczkowski TA. See Mann JJ
Millana R. See Boutros NNH
Miller BG. See Arvanitis LA
Miller FG, Rosenstein DL. Psychiatric symptom provoking studies: an ethical appraisal, 403
Minor TR, Saade S. Poststress glucose mitigates behavioral impairment in rats in the "learned helplessness" model of psychopathology, 324
Mirsky AF. See Jönsson EG
Mitchell J. See Unis AS
Miyaoka H, Suzuki Y, Taniyama M, Miyaoka Y, Shishikura K, Kamijima K, Atsumi Y, Matsuoka K. Mental disorders in diabetic patients with mitochondrial transfer RNA$^{LEU(UUR)}$ mutation at position 3243, 524
Miyaoka Y. See Miyaoka H
Mokhtar ASE, Morgan CJ, Bradley DM, Badawy AA-B. No early effects of electroconvulsive therapy on tryptophan metabolism and disposition in endogenous depression, 201
Mongeau R, Marsden CA. Effect of central and peripheral administrations of cholecystokinin—tetrapeptide on panic-like reactions induced by stimulation of the dorsal periaqueductal grey area in the rat, 335
Monteleone P, Catapano F, Bortolotti F, Maj M. Plasma prolactin response to *d*-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment, 175
Moorhead S. See Craddock N
Morault PM, Bourgeois M, Laville J, Bensch C, Paty J. Psychophysiological and clinical value of event-related potentials in obsessive-compulsive disorder, 46
Moreci P. See Kaufman J
Morgan CJ. See Mokhtar ASE
Mori N. See Ohara Koichi
Morrow LA. See Steinhauer SR
Moser M
See Lehofer M
See Liebmann PM
Mosheva T. See Rotenberg VS
Moynihan N. See Lindenmayer J-P
Mrak RE. See Omori M
Mulder RT
See Inder WJ
See Sullivan PF

Mullington J
See Hinze-Selch D
See Pollmächer T
Mulsant BH. See Sweet RA
Mundo E, Soldati L, Bellodi L, Bianchi G. The calpain–calpastatin system in obsessive- compulsive disorder, 228
Muralidharam R. See Malhotra S
Murase S. See Kitayama I
Murphy VE. See Mynett-Johnson LA
Murray RM. See Kunugi H
Murthy PJ. See Naga Venkatesha Murthy PJ
Myers H. See Chang L
Mynett Johnson L. See Craddock N
Mynett Johnson LA, Murphy VE, Manley P, Shields DC, McKeon P. Lack of evidence for a major locus for bipolar disorder in the pericentromeric region of chromosome 18 in Irish pedigrees, 486

Na DL. See Hong KS
Naga Venkatesha Murthy PJ, Murthy PJ, Gangadhar BN, Gangadhar BN, Janakiramaiah N, Subbakrishna DK. Normalization of P300 amplitude following treatment in dysthymia, 740
Nair C. See Verghese C
Nair NPV. See Ng Ying Kin NMK
Nakano K. See Kitayama I
Neels H. See Maes M
Nelson B. See Kaufman J
Nemetbakhsh MA. See Tracy JI
Nettles KW. See Luchins DJ
Ng Ying Kin NMK. See Martial J
Ng Ying Kin NMK, Nair NPV, Amin M, Schwartz G, Ahmed SK, Holm P, Katona C, Kragh-Sorensen P, Klitgaard N, Song W-Y, West TEG, Stage K, The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline, 925
Nierenberg AA. See Fava M
Nisbet RH. See Harper DN
Nishi N. See Odagaki Y
Nomura J. See Kitayama I
Nordqvist-Karlsson B. See Engström C
Nowacki R. See Olichney JM
Nowak H. See Hajek M
Nuechterlein KH. See Strandburg RJ

Nylander P-O. See Engström C

O'Connor WT. See Ferraro L
Odagaki Y, Nishi N, Koyama T, Lack of interfering effects of lithium on receptor/G protein coupling in human platelet and rat brain membranes, 697
O'Donovan MC. See Craddock N
Oertel J. See Klein P
Ohara Kenshiro. See Ohara Koichi
Ohara Koichi, Tani K, Tsukamoto T, Suzuki Y, Xu H-D, Xu D-S, Wang Z-C, Ohara Kenshiro. Exclusion of five trinucleotide repeat (CAG and CCG) expansions in 17 families with schizophrenia, 756
Ohara Koichi, Xu H-D, Mori N, Suzuki Y, Xu D-S, Ohara Kenshiro, Wang Z-C. Anticipation and imprinting in schizophrenia, 760
Ohguni S. See Inagaki T
Ohnuma S. See Masuda Y
O'Keane V. See Cooney JM
O'Leary DS. See Torres IJ
Oler MJ. See Martin CA
Olichney JM, Iragui VJ, Kutas M, Nowacki R, Jeste DV. N400 abnormalities in late life schizophrenia and related psychoses, 13
Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers, 1
Olsson K. See Weiner MF
Omori M, Pearce J, Komoroski RA, Griffin WST, Mrak RE, Husain MM, Karson CN. In vitro ^{1}H-magnetic resonance spectroscopy of postmortem brains with schizophrenia, 359
Orr SP. See Metzger LJ
Orth A. See Hinze-Selch D
Orth DN. See Geracioti TD Jr
O'Sullivan RL, Rauch SL, Breiter HC, Grachev ID, Baer L, Kennedy DN, Keuthen NJ, Savage CR, Manzo PA, Caviness VS, Jenike MA. Reduced basal ganglia volumes in trichotillomania measured via morphometric magnetic resonance imaging, 39
Otani M. See Kitayama I
O'Toole SM, Sekula LK, Rubin RT. Pituitary—adrenal cortical axis measures as predictors of sustained remission in major depression, 85
Owen MJ. See Craddock N
Özesmi Ç. See Dolu N

Palmar M, Marcano A, Castejon O. Fine structural alterations of blood platelets in depression, 965
Pande AC. See Crunhaus L
Papp LA. See Gorman JM
Paris J. See Martial J
Parnas J. See Eyler Zorrilla LT
Partonen T, Vakkuri O, Lönnqvist J. Suppression of melatonin secretion by bright light in seasonal affective disorder, 509
Patelis-Siotis I. See Young LT
Paty J. See Morault PM
Pava JA. See Fava M
Pavone L, Fiumara A, Bottaro G, Mazzone D, Coleman M. Autism and celiac disease: failure to validate the hypothesis that a link might exist, 72
Pearce J. See Omori M
Pellowski M. See Grillon C
Peralta V, Cuesta MJ, Farre C. Factor structure of symptoms in functional psychoses, 806
Perel JM
See Kaufman J
See Reynolds CF III
Perini G. See Brambilla F
Perl D. See Powchik P
Perlis ML, Giles DE, Buysse DJ, Thase ME, Tu X, Kupfer DJ. Which depressive symptoms are related to which sleep electroencephalographic variables?, 904
Perna G. See Brambilla F
Perna G, Bertani A, Politi E, Colombo G, Bellodi L. Asthma and panic attacks, 625
Pernhaupt G. See Liebmann PM
Perry BD. See Unis AS
Peterson JL. See Altman EG
Petit M. See Bonnet-Brilhault F
Petrakis IL. See Stine SM
Petrides G, Divadeenam KM, Bush G, Francis A. Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia, 375
Pettersson E. See Svartangren J
Peyrin L. See Curtin F
Pickar D. See Malhotra AK
Pickworth WB, Fant RV, Butschky MF, Goffman AL, Henningfield JE. Evaluation of cranial

electrostimulation therapy on short-term smoking cessation, 116
Pietrowsky R. See Wolf OT
Pillay SS, Yurgelun-Todd DA, Bonello CM, Lafer B, Fava M, Renshaw PF. A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar depression: relationship to treatment response and clinical severity, 79
Pitchot W. See Hansenne M
Pitman RK. See Metzger LJ
Poland RE
See Higley JD
See McCracken JT
Politi E. See Perna G
Pollmächer T. See Hinze-Selch D
Pollmächer T, Mullington J, Lauer CJ. REM sleep disinhibition at sleep onset: a comparison between narcolepsy and depression, 713
Pollock BG
See Laghrissi Thode F
See Sweet RA
Porjesz B
See Cohen HL
See Zhang XL
Powchik P, Friedman J, Haroutunian V, Greenberg D Altsteil L, Purohit D, Perl D, Davidson M. Apolipoprotein E4 in schizophrenia: a study of one hundred sixteen cases with concomitant neuropathological examination, 296
Powchik P. See Friedman J
Praestholm J. See Eyler Zorrilla LT
Price LH. See Cappiello A
Prickett TCR. See Inder WJ
Purohit D. See Powchik P

Quereshi G. See Tracy JI

Radant AD, Claypoole K, Wingerson DK, Cowley DS, Roy Byrne PP. Relationships between neuropsychological and oculomotor measures in schizophrenia patients and normal controls, 797
Ragan PW. See George DT
Rägo L. See Shlik J
Raine A, Buchsbaum M, LaCasse L. Brain abnormalities in murderers indicated by positron emission tomography, 495
Rambert F. See Ferraro L
Rauch SL. See O'Sullivan RL
Rauch SL, Savage CR, Alpert NM, Fischman AJ, Jenike MA. The functional neuroanatomy of anxiety: a study of three disorders using positron emission tomography and symptom provocation, 446
Reggers J. See Hansenne M
Remen A. See Grunhaus L
Renshaw PF
See deB Frederick B
See Pillay SS
Reuss S. See Dahmen N
Reynolds CF III, Buysse DJ, Brunner DP, Begley AE, Dew MA, Hoch CC, Hall M, Houck PR, Mazumdar S, Perel JM, Kupfer DJ. Maintenance nortriptyline effects on electroencephalographic sleep in elderly patients with recurrent major depression: double-blind, placebo- and plasma-level-controlled evaluation, 560
Risser RC. See Weiner MF
Ritter LM, Meador-Woodruff JH. Antipsychotic regulation of hippocampal dopamine receptor messenger RNA expression, 155
Ritter W. See Kazmerski VA
Robb JC. See Young LT
Roberts BB. See Escalona PR
Robertson MM. See Brett PM
Romańska I. See Antkiewicz-Michaluk L
Röschke J. See Mann K
Rosen J
See Intrator J
See Sweet RA
Rosenbaum JF. See Fava M
Rosenstein DL. See Miller FG
Rosenthal NE. See Schwartz PJ
Ross DE, Thaker GK, Buchanan RW, Kirkpatrick B, Lahti AC, Medoff D, Bartko JJ, Goodman J, Tien A. Eye tracking disorder in schizophrenia is characterized by specific motor defects and is associated with the deficit syndrome, 781
Rossi A
See Daniele A
See Stratta P
Rotenberg VS, Hadjez J, Kimhi R, Indurski P, Sirota P, Mosheva T, Benatov R, Elizur A. First night effect in depression: new data and a new approach, 267
Rothermundt M, Arolt V, Weitzsch C. Cytokines in schizophrenia, 308-corr (response)
Rothman RB. See Gorelick DA
Roux S, Bruneau N, Garreau B, Guérin P, Adrien J-L, Dansart P, Gomot M, Barthélémy C. Bioclinical profiles of autism and other developmental disorders using a multivariate statistical approach, 1148
Rowan MJ. See Swanwick GRJ
Roy A. See Roy M
Roy M, Roy A, Smelson D, Brown S, Weinberger L. Reduced blue cone electroretinogram in withdrawn cocaine dependent patients: a replication, 631
Roy-Byrne PP. See Radant AD
Rubin RT, See O'Toole SM
Ruegg RG, Gilmore J, Ekstrom RD, Corrigan M, Knight B, Tancer M, Leatherman ME, Carson SW, Golden RN. Clomipramine challenge responses covary with Tridimensional Personality Questionnaire scores in healthy subjects, 1123
Ruiz P. See Johnson BA
Ruscheinsky DD. See Arnold SE
Ryan ND. See Kaufman J

Saade S. See Minor TR
Sachs G. See Vasile RG
Samolyk D. See Bonnet-Brilhault F
Satlin A. See deB Frederick B
Satz P. See Chang L
Sauer H. See Hajek M
Savage CR
See O'Sullivan RL
See Rauch SL
Sax KW. See Strakowski SM
Schaefer C. See Intrator J
Schauenstein K. See Liebmann PM
Schenck CH, Mahowald MW. Lewy body variant of Alzheimer' s disease (AD) identified by postmortem ubiquitin staining in a previously reported case of AD associated with REM sleep behavior disorder, 527-corr
Schmeidler J. See Stern RG
Schmitz J. See Johnson BA
Schulsinger F. See Eyler Zorrilla LT
Schulz P. See Curtin F
Schwartz G
See Martial J
See Ng Ying Kin NMK
Schwartz GE, See Lane RD
Schwartz PJ, Rosenthal NE, Turner EH, Drake CL, Liberty V, Wehr TA.

Seasonal variation in core temperature regulation during sleep in patients with winter seasonal affective disorder, 122
Scott E. See Hickie I
Sedvall GC. See Jönsson EG
Seidman LJ, Goldstein JM, Goodman JM, Koren D, Turner WM, Faraone SV, Tsuang MT. Sex differences in olfactory identification and Wisconsin Card Sorting Performance in schizophrenia: relationship to attention and verbal ability, 104
Sekula LK. See O'Toole SM
Sellman JD. See Sullivan PF
Seno H. See Inagaki T
Sernyak MJ. See Cappiello A
Seroquel Trial 13 Study Group. See Arvanitis LA
Setters MJ. See Strakowski SM
Shanahan/Silipo G. See Winsberg BG
Shields DC. See Mynett-Johnson LA
Shimizu T. See Masuda Y
Shipley JE. See Grunhaus L
Shishikura K. See Miyaoka H
Shlik J, Vasar V, Aluoj a A, Kingisepp P-H, Jagoñagi K, Vasar E, Rägo L, Bradwejn J, The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers, 206
Shohat B. See Spivak B
Siegert RJ. See Harper DN
Sim C-B. See Lan T-H
Simpson SG. See MacKinnon DF
Singh B. See Marzella PL
Sirota P. See Rotenberg VS
Slaap BR. See van Vliet IM
Smelson D. See Roy M
Smith RD. See Tupler LA
Sokolov ST. See Young LT
Soldati L. See Mundo E
Song W-Y. See Ng Ying Kin NMK
Soulier V. See Curtin F
Spivak B, Shohat B, Mester R, Avraham S, Gil-Ad I, Bleich A, Valevski A, Weizman A. Elevated levels of serum interleukin-1β in combat-related posttraumatic stress disorder, 345
Stage K. See Ng Yinq Kin NMK
Stanton SP. See Strakowski SM
Stein MB, Yehuda R, Koverola C, Hanna C, Enhanced dexamethasone suppression of plasma cortisol in adult women traumatized by childhood sexual abuse, 680
Steinhauer SR, Morrow LA, Condray R, Dougherty GG Jr. Event-related potentials in workers with ongoing occupational exposure, 854
Stern RG, Schmeidler J, Davidson M. Limitations of controlled augmentation trials in schizophrenia, 138
Stevens JR, Denney D, Szot P, Sensitization with clozapine: beyond the dopamine hypothesis, 771
Stine OC. See Kato T
Stine SM, Krystal JH, Petrakis IL, Jatlow PI, Heninger GR, Kosten TR, Charney DS. Effect of alpha-methyl-para- tyrosine on response to cocaine challenge, 181
Stokes PE. See Mann JJ
Strakowski SM, Sax KW, Setters MJ, Keck PE Jr. Stimulant sensitization in humans, 230-corr (response)
Strakowski SM, Sax KW, Setters MJ, Stanton SP, Keck PE Jr. Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosisis: implications for a sensitization model of psychosis in humans, 749
Strandburg RJ, Marsh JT, Brown WS, Asarnow RF, Guthrie D, Harpe: R, Yee CM, Nuechterlein KH. Event-related potential correlates of linguistic information processing in schizophrenia, 596
Stratta P, Mancini F, Mattei P, Daneluzzo E, Casacchia M, Rossi A. Association between striatal reduction and poor Wisconsin Card Sorting Test performance in patients with schizophrenia, 816
Stritzke P. See Intrator J
Süer. See Dolu N
Subbakrishna DK. See Naga Venkatesha Murthy PJ
Suckow R. See FitzGerald M
Suh Y-L. See Hong KS
Sullivan PF. See Inder WJH
Sullivan PF, Fifield WJ, Kennedy MA, Mulder RT, Sellman JD, Joyce PR. Novelty seeking and a dopamine transporter gene polymorphism *(DATl)*, 1070
Suzuki Y
See Miyaoka H
See Ohara Koichi
Svartangren J, Pettersson E, Björk A. Interaction of the novel antipsychotic drug amperozide and its metabolite FG5620 with central nervous system receptors and monoamine uptake sites: relation to behavioral and clinical effects, 247
Svetlik D. See Weiner MF
Swann AC. See Johnson BA
Swanwick GRJ, Rowan MJ, Coen RF, Lawlor BA, Walsh JB, Coakley D. Electrophysiologic responses to varying mnemonic demand: a "stress test" is not diagnostic in very mild Alzheimer's disease, 1182
Swayze V II. See Torres IJ
Sweeney JA. See Mann JJ
Sweet RA, Pollock BG, Mulsant BH, Rosen J, Lo KH, Yao JK, Henteleff RA, Mazumdar S. Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report, 1016
Szczudlik A, See Antkiewicz-Michaluk L
Szot P. See Stevens JR
Szuba MP, Guze BM, Baxter LR Jr. Electroconvulsive therapy increases circadian amplitude and lowers core body temperature in depressed subjects, 1130

Tabakoff B. See Menninger JA
Tanaka J. See Inagaki T
Tancer M. See Ruegg RG
Tandon R. See Grunhaus L
Tanganelli S. See Ferraro L
Tani K. See Ohara Koichi
Taniyama M. See Miyaoka H
Taub DM. See Higley JD
Teboul E. See Martial J
Thaker GK. See Ross DE
Thase ME, See Perlis ML
Thavundayil J. See Martial J
Thibaut F. See Bonnet-Brilhault F
Tien A. See Ross DE
Tohen M. See Zarate CA
Torres IJ, Flashman LA, O'Leary DS, Swayze V II, Andreasen NC. Lack of an association between delayed memory and hippocampal and temporal lobe seizure in patients with schizophrenia and healthy controls, 1087
Tracy JI, Nemetbakhsh MA, de Leon J, McCann EM, McGrory A, auereshi

G, Josiassen RC. A comparison of polydipsia prevalence among chronic psychiatric patients using three measurement approaches, 1097
Tsuang MT. See Seidman LJ
Tsukamoto T. See Ohara Koichi
Tsutsumi T, See Akiyoshi J
Tu X. See Perlis ML
Tupler LA, Davidson JRT, Smith RD, Lazeyras F, Charles HC, Krishnan KRR. A repeat proton magnetlc resonance spectroscopy study in social phobia, 419
Turner EH. See Schwartz PJ
Turner WM. See Seidman LJ

Uebelacker LA. See Fava MH
Underwood K. See Garvey MJ
Unis AS, Cook EH, Vincent JG, Gjerde DK, Perry BD, Mason C, Mitchell J. Platelet serotonin measures in adolescents with conduct disorder, 553

Vakkuri O. See Partonen T
Valevski A. See Spivak B
Vallada HP. See Kunugi H
Vandoolaeghe E. See Maes M
van Kammen DP
See Gilbertson MW
See Jönsson EG
van Vliet IM, Westenberg HGM, Slaap BR, den Boer JA, Ho Pian KL. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls, 76
Vasar E. See Shlik J
Vasar V. See Shlik J
Vasavan Nair NP. See Martial J
Vasile RG, Sachs G, Anderson JL, Lafer B, Matthews E, Hill T. Changes in regional cerebral blood flow following light treatment for seasonal affective disorder: responders versus nonresponders, 1000
Verghese C, Levitan I, Nair C, Abraham G, Garber SS, Josiassen RC. Impaired Iymphocyte volume regulation in schizophrenic patients with polydipsia-hyponatremia, 733
Vestergaard A. See Eyler Zorrilla LT
Vetulani J
See Antkiewicz-Michaluk LH
See Zyss T
Viitanen M. See Forsell Y
Vincent JG. See Unis AS
Vital-Herne M. See Lindenmayer J-F
Vobach S. See Weiner MF
Volz H-P. See Hajek M
Vore M. See Martin CA

Wagner WR. See Laghrissi-Thode F
Wahlström J. See Jönsson EG
Walker DL, Davis M. Anxiogenic effects of high illumination levels assessed with the acoustic startle response in rats, 461
Walker J-P. See Curtin F
Walsh JB. See Swanwick GRJ
Walzer C. See García-Sevilla JA
Wang W. See Cohen HL
Wang Z-C. See Ohara Koichi
Wauters A. See Maes M
Wehr TA. See Schwartz PJ
Weinberger L. See Roy M
Weiner MF, Vobach S, Olsson K, Svetlik D, Risser RC. Cortisol secretion and Alzheimer's disease progression, 1030
Weiner RD. See Freudenreich C
Weitzsch C. See Rothermundt M
Weizman A. See Spivak B
Welkowitz L. See Gorman JM
Wells W. See Kaufman J
West TEG. See Ng Ying Kin NMK
Westenberg HGM. See van Vliet IM
Wiedemann K, Holsboer F. The effect of repeated human corticotropin releasing hormone administration on dexamethasone-suppressed pituitary adrenocortical activity in healthy subjects, 882
Wilhelm K. See Hickie I
Wilner PJ. See Mann JJ
Winblad B. See Forsell Y
Wingerson DK. See Radant AD
Winokur G. See Kato T
Winsberg BG, Javitt DC, Shanahan/Silipo G. Electrophysiological indices of information processing in methylphenidate responders, 434
Wolf OT, Köster B, Kirschbaum C, Pietrowsky R, Kern W, Hellhammer DH, Born J, Fehm HL. A single administration of dehydroepiandrosterone does not enhance memory performance in young healthy adults, but immediately reduces cortisol levels, 845
Woods CM. See Young LT

Xu D-S. See Ohara Koichi
Xu H-D. See Ohara Koichi
Yaga T. See Kitayama I
Yamada K. See Akiyoshi J
Yamamoto Y. See Akiyoshi J
Yang R-K, Yehuda R, Holland DD, Knott PJ. Relationship between 3-methoxy-4 hydroxyphenylglycol and homovanillic acid in saliva and plasma of healthy volunteers, 821
Yao JK. See Sweet RA
Yatham LN, Lam RW, Zis AP. Growth hormone response to sumatriptan (5-HTID agonist) challenge in seasonal affective disorder, 24
Yee CM. See Strandburg RJ
Yehuda R
See Kellner M
See Stein MB
See Yang R-K
Young DA. See Olincy A
Young LT, Robb JC, Patelis-Siotis I, MacDonald C, Joffe RT. Acute treatment of bipolar depression with gabapentin, 851
Young LT, Woods CM, Robb JC, Patelis-Siotis I, Asghari V, Sokolov ST. Platelet endogenous adenosine 5-diphosphate ribosylation in drug-free and lithium treated subjects with bipolar disorder, 413
Yurgelun-Todd DA
See deB Frederick B
See Pillay SS
Zapotoczky H-G. See Lehofer M
Zarate CA, Tohen M, Zarate SB. Thyroid function tests in first-episode bipolar disorder manic and mixed types, 302
Zarate SB. See Zarate CA
Zhang XL, Begleiter H, Porjesz B, Litke A. Electrophysiological evidence of memory impairment in alcoholic patients, 1157
Zis AP. See Yatham LN
Zweig Frank H. See Martial J
Zyss T, Górka Z, Kowalska M, Vetulani J. Preliminary comparison of behavioral and biochemical effects of chronic transcranial magnetic stimulation and electroconvulsive shock in the rat, 920

Subject Index to Volume 42

Abstinence
  cocaine, neurochemical alterations and, 1105
Acetylcholine
  pyridostigmine/growth hormone challenge in depression and, 827
Acoustic startle reflex
  darkness and, 453
  light enhancement of, 461
Activation factor
  heterogeneity of serotonergic response in schizophrenia and, 6
Acute phase proteins
  zinc serum level in major depression and, 349
Addiction
  opiate, 962
Add-on treatments
  controlled augmentation trials in schizophrenia and, 138
Adenosine 5'-diphosphate ribosylation
  platelet, bipolar disorder and, 413
Adenosine triphosphate (ATP)
  lactate-induced panic attacks in alcoholism and, 992
Adenylyl cyclase
  major depression and, 30, 859
Adolescents
  conduct disorder in, platelet serotonin measures and, 553
  depression in, scopolamine and, 577
Adrenergic receptors
  amperozide receptor binding and, 247
Adrenocorticotropic hormone (ACTH)
  CSF CRH in eucortisolemic depression and, 166
  hypothalamic-pituitary-adrenal predictors of remission in depression and, 85
Affect
  darkness and acoustic startle reflex, 453
Affective disorders
  catechol-*o*-methyltransferase and, 282
  family history of correlated with lithium therapy, 425
  leukocyte mtDNA deletion in, 311
  mtDNA deletion in bipolar disorder and, 871
  REM sleep disinhibition at sleep onset and, 713
Affective processing
  SPECT study in psychopaths and, 96
Age
  apolipoprotein E polymorphism in a population sample age 75 +, 898
  depression and, 925
  first night effect in depression and, 267
  gray matter volume and depression severity, 79
  IL-1β in PTSD and, 345
  lithium therapy history of affective disorders, 425
  major depression and cardiac autonomic control, 914
  mtDNA deletion in bipolar disorder and, 871
  N400 in late-life schizophrenia and, 13
  obsessive-compulsive disorder and, 889, 976
  OCD following globus pallidus infarction and, 410
  PET of murderers and, 495
  platelet factor 4 and β-thromboglobulin with ischemic heart disease in depression, 290
  schizophrenia and, 648, 797
  serotonin and conduct disorder in adolescents, 553
  subcortical hyperintensities in major depression and, 367
Aggression
  serotonin and 305-corr, 306-corr (response), 546, 553
Alcoholism
  chronic cocaine dependence in, 472
  lactate-induced panic attacks in, 992
  memory impairment in, 1157
  neuroleptic correlates of response production in, 57
  progesterone and adolescent suicidality, 956
  pyridostigmine/growth hormone challenge in depression and, 827
Alexithymia
  blindsight and, 834
  IL-1β in PTSD and, 345
Alleles
  catechol-*o*-methyltransferase, affective disorders and, 282
  exclusion of five trinucleotide repeat (CAG and CCG) expansion in schizophrenia and, 756
  Tourette's syndrome and, 941
α_1-adrenergic receptors
  amperozide receptor binding and, 247
Alpha-methyl-para-tyrosine
  cocaine challenge and, 181
Altman self-rating mania scale
  overview, 948
Alzheimer's disease

© 1997 Society of Biological Psychiatry

0006-3223/97/$17.00
PII S0006-3223(97)00503-9

apolipoprotein E4 and, 225, 296
familial, pedigree analysis in, 1172
homovanillic acid and behavioral symptoms, 1016
hypercortisolemia and, 1030
mnemonic demand in, 1182
in parietal and temporal lobes, proton magnetic resonance spectroscopy of, 147
Lewy body variant of, 527-corr
mismatch negativity and, 382
stress test in, 1181
Amino acids
amperozide receptor binding and, 247
CCK-4 in panic-like reactions and, 335
ECT and tryptophan metabolism in depression, 201
in vitro ^{1}H-magnetic resonance spectroscopy in schizophrenia and, 359
Tourette's syndrome and, 941
Amperozide
receptor binding and, 247
d-Amphetamine
modafinil and, 1181
repeated challenge, first-episode psychosis in, 749
Amplitude
auditory evoked magnetic fields in left hemisphere in schizophrenia and, 609
chronic cocaine dependence and, 472
dysthymia and, 740
ERPs in workers with ongoing occupational exposure, 854
event-related potentials in OCD and, 46
linguistic ERPs in schizophrenia and, 596
methylphenidate and ERP components, 434
mismatch negativity in Alzheimer's disease and, 382
N400 in late-life schizophrenia and, 13
neuroleptic correlates of response production and, 57
parametric study and, 1051
posttraumatic stress disorder and, 1006
repeat ^{1}H-MRS in social phobia and, 419
Amygdala
PET of murderers and, 495
Analgesia
persistent, former opiate addicts and, 962
Anterior cingulate cortex
alexithymia and, 834
Antibodies
autism and celiac disease, 72
Anticipation
CAG/CTG repeats in bipolar disorder and, 876
lithium therapy history of affective disorders, 425
schizophrenia and, 760
Anticonvulsants
bipolar disorder and, 851
Antidepressants
desipramine in immediate early gene expression and, 317
ECT and, 920
forskolin-stimulated platelet adenylyl cyclase in major depression and, 30
G protein density in major depression and, 704
major depression and cardiac autonomic control, 914
serotonin transporter mRNA and, 1073
transcranial magnetic stimulation and, 920
zinc serum level in major depression and, 349
Antipsychotics
hippocampal dopamine receptor mRNA regulation and, 155
NMDA-induced psychosis and, 664
pimozide with, schizophrenia and, 522
quetiapine in schizophrenia and, 233
serotonin in schizophrenia and, 529
sleep and, 260
Antisaccades
schizophrenia and, 797
Antonymic relationship
N400 in late-life schizophrenia and, 13
Anxiety
CCK-4 in panic-like reactions and, 335
darkness and acoustic startle reflex, 453
IL-1β in PTSD and, 345
light enhancement of acoustic startle reflex and, 461
major depression and cardiac autonomic control, 914
mitochondrial transfer RNA$^{Leu(UUR)}$ mutation in diabetes and, 524
neuroanatomy of, 446
OCD following globus pallidus infarction and, 410
pentagastrin in social phobia and, 76
Anxious depression
treatment response and, 568
Apolipoprotein E4
schizophrenia and, 225, 296
Apomorphine
obsessive-compulsive disorder and, 889
Arginine vasopressin
hypercortisolemia and suicide attempts in depression, 744
Arousal
heightened, depressive symptoms related to sleep EEG variables, 904
hyperthyroidism and, 1024
Aspirin use
platelet factor 4 and β-thromboglobulin with ischemic heart disease in depression, 290
Association studies
affective disorders and catechol-*o*-methyltransferase, 282
novelty seeking and *DAT1* dopamine transporter gene polymorphism, 1070
serotonin transporter gene polymorphism and schizophrenia, 634
Asymmetry
during cognitive task performance in depression, 1039
Asthma
panic attacks and, 625
Attend conditions
mismatch negativity in Alzheimer's disease and, 382
Attentional deficits
gender differences in schizophrenia and, 104
Attention deficit hyperactivity disorder (ADHD)
methylphenidate and ERP components, 434

Atypical depression
CSF CRH in, 166
treatment response and, 568
Atypical psychosis
factor structure symptoms in, 806
Auditory event-related potentials
chronic cocaine dependence and, 472
N40 amplitude and, 1051
to tone stimuli, PTSD and, 1006
Auditory evoked magnetic fields
schizophrenia and, 609
Auditory oddball task
methylphenidate and ERP components, 434
Augmentation
controlled trials, schizophrenia and, 138
pimozide, schizophrenia and, 522
Autism
celiac disease link with, 72
multivariate statistical approach to, 1148
neural circuit theory of, 1138
Autonomic control
cardiac, major depression and, 914
Aversive stimuli
light enhancement of acoustic startle reflex and, 461
Avoidance behavior
reward dependence and monoamines, 275

Basal ganglia
OCD following globus pallidus infarction and, 410
volumes, morphometric MRI in trichotillomania and, 39
Beck Depression Inventory
sleep EEG variables and, 904
Behavioral effects
amperozide receptor binding and, 247
ECT and, 920
homovanillic acid in dementia and, 1015
primate aggression and serotonin, 305-corr, 306-corr (response)
glucose prophylaxis and learned helplessness, 324
reward dependence and monoamines, 275
schizophrenia and, 760, 816, 1087
serotonin and conduct disorder in adolescents, 553
serotonin and fluoxetine, 546
temporal lobe epilepsy and, 617
transcranial magnetic stimulation and, 920
Behavioral sensitization
repeated *d*-amphetamine challenge in first-episode psychosis and, 749
Benzodiazepines
amperozide receptor binding and, 247
lorazepam with ECT for catatonia and, 375
Benzoylecgonine
ritanserin for cocaine dependence and, 932
β-adrenergic receptors
adenylyl cyclase-coupled, major depression and, 859
Binding affinity profile
amperozide, 247
Biochemical effects
amperozide receptor binding and, 247
ECT and, 920
transcranial magnetic stimulation and, 920
Biopsy
autism and celiac disease, 72
Bipolar disorder
affective disorders and catechol-*o*-methyltransferase, 282
CAG/CTG repeats in, 876, 1115
clozapine treatment of paroxysmal dyskinesia associated with concomitant paroxetine/sumatriptan use, 144
familial, panic disorder with, 90
gabapentin in, 851
leukocyte mtDNA deletion in, 311
lithium therapy history of affective disorders, 425
mtDNA deletion in, 871
pericentromeric region of chromosome 18 in Irish pedigrees and, 486
platelet adenosine 5'-diphosphate ribosylation in, 413
thyroid function tests in, 302
tryptophan depletion in lithium-remitted mania and, 1076
Blindsight
alexithymia and, 834
Blockade
endogenous opioid, persistent analgesia in former opiate addicts, 962
Blocking effect
dietary gluten and, 1060
Blood pressure
alpha-methyl-para-tyrosine and cocaine challenge, 181
Blue cone electroretinogram
reduced, cocaine withdrawal and, 631
Blunting
adenylyl cyclase-coupled receptors in major depression and, 859
growth hormone response to sumatriptan in SAD and, 24
heterogeneity of serotonergic response in schizophrenia and, 6
NMDA-induced psychosis and, 664
Body temperature
seasonal variation in core temperature and, 122
Borderline personality disorder
serotonin function and, 737
Brain
ECT and tryptophan metabolism in depression, 201
in vitro ^{1}H-magnetic resonance spectroscopy in schizophrenia and, 359
neuroanatomy of anxiety and, 446
Brainstem
neuroanatomy of anxiety and, 446
pontine vascular depression in depression and, 519
Breathing
disordered, panic disorder and, 982
Brief Psychiatric Rating Scale
quetiapine in schizophrenia and, 233
Brief reactive psychosis
factor structure symptoms in, 806
Bright light

melatonin suppression by, in SAD, 509
British Isles pedigrees
CAG/CTG repeats in bipolar disorder and, 876
British kindred
Tourette's syndrome and, 941
Bronchoconstriction
CCK-4 effects on respiratory resistance and, 206
Buspirone
light enhancement of acoustic startle reflex and, 461
t-Butoxycarbonyl cholecystokinin
tetrapeptide, panic-like reactions and, 335
Button press
neuroleptic correlates of response production and, 57

Caffeine
use, as counfound in psychiatric studies, 1172
CAG/CCG repeat expansion
exclusion of in schizophrenia, 756
CAG/CTG repeat
bipolar disorder and, 876, 1115
Calbindin-D28k
cerebellum in schizophrenia and, 213
Calcifications
cerebral, autism and celiac disease, 72
Calcium
amperozide receptor binding and, 247
intracellular mobilizatyion, CCK-4-induced, 151
Calpain-calpastatin system
obsessive-compulsive disorder and, 228
Carbon dioxide
panic disorder and, 982
Carbon monoxide
cranial electrostimulation therapy in smoking cessation and, 116
Cardiac autonomic control
major depression and, 914
Catatonia
factor structure symptoms in, 806
lorazepam with ECT for, 375
Catecholamines
adenylyl cyclase-coupled receptors in major depression and, 859
Catechol-*o*-methyltransferase
affective disorders and, 282
Categorical relationship
N400 in late-life schizophrenia and, 13
Catheterization
indwelling subarachnoid, CSF CRH in eucortisolemic depression and, 166
Caucasian pedigrees
CAG/CTG repeats in bipolar disorder and, 876
Caudate putamen
basal ganglia volume in trichotillomania and, 39
schizophrenia and, 648, 816
Celiac disease
autism link with, 72
Cell culture
desipramine in immediate early gene expression and, 317
Cell-mediated immunity
zinc serum level in major depression and, 349
Central nervous system (CNS)
amperozide receptor binding and, 247
Centralis superior
pontine vascular depression in depression and, 519
Cerebellar vermis
in vitro ^{1}H-magnetic resonance spectroscopy in schizophrenia and, 359
Cerebellum
gray matter volume and depression severity, 79
schizophrenia and, 213
Cerebral blood flow
neuroanatomy of anxiety and, 446
regional, after light treatment for SAD, 1000
SPECT study in psychopaths and, 96
Cerebral cortex
alexithymia and, 834
amperozide receptor binding and, 247
cerebellum in schizophrenia and, 213
chronic cocaine dependence and, 472
ECT and, 920
mtDNA deletion in bipolar disorder and, 871
neuroanatomy of anxiety and, 446
noradrenergic axons, effect of imipramine or stress on, 687
PET of murderers and, 495
repeat ^{1}H-MRS in social phobia and, 419
subcortical hyperintensities in major depression and, 367
transcranial magnetic stimulation and, 920
Cerebrospinal fluid (CSF)
CRH, eucortisolemic depression and, 166
in Parkinson's disease, salsolinol and, 514
Cerebrovascular disease
subcortical hyperintensities in major depression and, 367
Cesium fluoride
forskolin-stimulated platelet adenylyl cyclase in major depression and, 30
c-fos
desipramine in immediate early gene expression and, 317
sensitization with clozapine and, 771
Challenge studies
anxiogenic effects of pentagastrin in social phobia and, 76
Charm
SPECT study in psychopaths and, 96
Chemiconvulsants
desipramine in immediate early gene expression and, 317
Childhood abuse
corticotropin-releasing hormone challenge and, 669
dexamethasone suppression in adult women traumatized by childhood sexual abuse and, 680
Children
corticotropin-releasing hormone challenge in, 669
darkness and acoustic startle reflex in, 453
methylphenidate and ERP components in, 434
serotonin and conduct disorder in adolescents, 553
Chlorophenylpiperazine (mCPP)
heterogeneity of serotonergic response in schizophrenia

and, 6
Cholecystokinin (CCK)
anxiogenic effects of pentagastrin in social phobia and, 76
Cholecystokinin tetrapeptide (CCK-4)
calcium mobilization in T cells induced by, 151
panic-like reactions and, 335
respiratory resistance and, 206
Choline
repeat ^{1}H-MRS in social phobia and, 419
Cholinergic regulation
pyridostigmine/growth hormone challenge in depression and, 827
sleep in depressed adolescents and, 577
Chromosome 18
pericentromeric region of in Irish pedigrees, bipolar disorder and, 486
Circadian rhythms
CSF CRH in eucortisolemic depression and, 166
depression and, 1130
seasonal variation in core temperature and, 122
Citalopram
G protein density in major depression and, 704
c-jun
desipramine in immediate early gene expression and, 317
Clicks
N40 amplitude and, 1051
Clomipramine
challenge, Tridimensioanl Personality Questionnaire and, 1123
G protein density in major depression and, 704
Clonazepam
repeat ^{1}H-MRS in social phobia and, 419
Clozapine
EEG changes and, 132
heterogeneity of serotonergic response in schizophrenia and, 6
hippocampal dopamine receptor mRNA regulation and, 155
NMDA-induced psychosis and, 664
persistent paroxysmal dyskinesia associated with concomitant paroxetine/sumatriptan use, 144
pimozide with, schizophrenia and, 522
sensitization and, 771
sleep and, 260
Cluster analysis
reward dependence and monoamines, 275
Clustered dispersion
neuronal, entorhinal cortex in schizophrenia and, 639
Clusters
gene, Tourette's syndrome and, 941
Cocaine
abstinence, neurochemical alterations and, 1104
alpha-methyl-para-tyrosine and cocaine challenge, 181
chronic dependence, P3A effects on, 472
dependence, ritanserin and, 932
electroretinogram, in withdrawn patients, 631
Cognitive behavioral therapy
panic disorder and, 982
Cognitive function
depression and, 1039
depressive symptoms related to sleep EEG variables, 904
dietary gluten and, 1060
event-related potentials in OCD and, 46
gender differences in schizophrenia and, 104
salsolinol in parkinsonian CSF and, 514
schizophrenia and, 585, 816
sialic acid reactivity and mental retardation, 68
subcortical hyperintensities in major depression and, 367
Coherence
EEG, schizophrenia and, 655
Cold pressor test
persistent analgesia in former opiate addicts, 962
Combat veterans
auditory event-related potentials to tone stimuli and, 1006
interleukin 1β and, 345
salivary cortisol in PTSD and, 849
Complex partial seizures
temporal lobe epilepsy and, 617
Computed tomography (CT)
structural brain abnormalities in schizophrenia and, 1080
Confounds
in psychiatric studies, nicotine and caffeine use as, 1177
Congruence
semantic, N400 in late-life schizophrenia and, 13
Consciousness
alexithymia and, 834
Consolidation
schizophrenia and, 1087
Continuity
sleep in depressed adolescents and, 577
Continuous performance challenge task
PET of murderers and, 495
Control issues
SPECT study in psychopaths and, 96
Convulsive seizures
sensitization with clozapine and, 771
Copper
zinc serum level in major depression and, 349
Core body temperature
depression and, 1130
nocturnal, seasonal variation in during sleep in winter SAD, 122
Corpus callosum
PET of murderers and, 495
Cortical feature maps
inadequate, autism and, 1138
Corticotropin
arginine vasopressin in depression and, 744
corticotropin-releasing hormone challenge in children and, 669
CSF CRH in eucortisolemic depression and, 166
hypothalamic-pituitary-adrenal predictors of remission in depression and, 85
Corticotropin-releasing hormone (CRH)
arginine vasopressin in depression and, 744

challenge, children and, 669
CSF, CRH in eucortisolemic depression and, 166
CSF, eucortisolemic depression and, 166
hypothalamic-pituitary-adrenal predictors of remission in depression and, 85
repeated administration, DST-suppressed pituitary-adrenocortical activity and, 882
Cortisol
Alzheimer's disease and, 1030
arginine vasopressin in depression and, 744
corticotropin-releasing hormone challenge in children and, 669
CSF CRH in eucortisolemic depression and, 166
dexamethasone suppression in adult women traumatized by childhood sexual abuse and, 680
DHEA and, 845
heterogeneity of serotonergic response in schizophrenia and, 6
hypothalamic-pituitary-adrenal predictors of remission in depression and, 85
IL-1β in PTSD and, 345
salivary, PTSD and, 849
serotonin function in borderline personality disorder and, 737
COS7 cells
amperozide receptor binding and, 247
Cotinine
cranial electrostimulation therapy in smoking cessation and, 116
levels in schizophrenic smokers, 1
Coupling proteins
adenylyl cyclase-coupled receptors in major depression and, 859
Cranial electrostimulation therapy
short-term smoking cessation and, 116
Creatine
cocaine abstinence and, 1105
Creatinine
repeat ^{1}H-MRS in social phobia and, 419
Cyclic adenosine monophosphate (cAMP)
adenylyl cyclase-coupled receptors in major depression and, 859
ECT and, 920
transcranial magnetic stimulation and, 920
Cytoarchitecture
entorhinal cortex, schizophrenia and, 639
Cytokines
obsessive-compulsive disorder and, 1186-corr
schizophrenia and, 308-corr, 308-corr (response)
zinc serum level in major depression and, 349
Cytoskeleton
cerebellum in schizophrenia and, 213

Darkness
startle reactivity and, 453
Deficit syndrome
eye tracking disorder in schizophrenia and, 781
Dehydroepiandrosterone (DHEA)
cortisol level reduction and, 845
Delayed memory
schizophrenia and, 1087
Deletion
leukocyte mtDNA, affective disorders and, 311
Delta sleep
depressive symptoms related to sleep EEG variables, 904
first night effect in depression and, 267
Delusions
factor structure symptoms in, 806
Dementia
apolipoprotein E4 and, 225, 296, 898
homovanillic acid and behavioral symptoms, 1015
salsolinol in parkinsonian CSF and, 514
subcortical hyperintensities in major depression and, 367
Depletion strategy
alpha-methyl-para-tyrosine and cocaine challenge, 181
Depression
adenylyl cyclase-coupled receptors in, 859
adolescent, scopolamine in, 577
affective disorders and catechol-*o*-methyltransferase, 282
apolipoprotein E polymorphism in a population sample age 75 +, 898
arginine vasopressin in, 744
brain electrical asymmetries during cognitive task performance in, 1039
CAG/CTG repeats in, 876
cardiac autonomic contol in, 914
CCK-4-induced calcium mobilization in T cells in, 151
cerebral cortex noradrenergic axons in, 687
CRH in, 166, 669
ECT in, 201, 1130
factor structure symptoms in, 806
first night effect in, 267
forskolin-stimulated platelet adenylyl cyclase in, 30
gabapentin in, 851
glucose prophylaxis and learned helplessness in, 324
G protein density in, 704
gray matter volume in, 79
growth hormone response to sumatriptan in, 24
hypercortisolemia in, 744
hyperthyroidism without, 1024
hypothalamic-pituitary-adrenal predictors of remission in, 85
IL-1β in PTSD and, 345
imipramine in, 687
ischemic heart disease with, platelet factor 4 and β-thromboglobulin in, 290
leukocyte mtDNA deletion in, 311
long-term stress in, 687
melatonin suppression in, 509
mitochondrial transfer $RNA^{Leu(UUR)}$ mutation in diabetes and, 524
mtDNA deletion in, 871
platelets in, 704, 965
pontine vascular malformation in, 519
posttraumatic stress disorder in, 1006

pyridostigmine/growth hormone challenge in, 827
REM sleep disinhibition at sleep onset in, 713
seasonal variation in core temperature regulation during sleep in, 122
serotonin in, 959
sleep EEG in, 560, 904
sleep-onset rapid eye movement after ECT in, 191
subcortical hyperintensities in, 367
subtypes, treatment response and, 568
suicide attempts in, 744
Tridimensional Personality Questionnaire in, 959
tryptophan metabolism in, 201
zinc serum level in, 349
Desipramine
immediate early gene expression and, 317
Dexamethasone suppression test (DST)
in adult women traumatized by childhood sexual abuse, 680
moclobemide and, 925
nortriptyline and, 925
pituitary-adrenocortical activity suppressed by, CRH and, 882
salivary cortisol in PTSD and, 849
Diabetes mellitus
mental disorders in, 524, 1067
Diet
gluten and, 1060
Differential contour algorithms
basal ganglia volume in trichotillomania and, 39
Dishabituation
N40 amplitude and, 1051
Disinhibition
at REM sleep onset, 713
Diurnal rhythm
CSF CRH in eucortisolemic depression and, 166
Dominance
cerebral, temporal lobe epilepsy and, 617
Dominance behavior
as confounding factor in studies of primate aggression and serotonin, 305-corr, 306-corr (response)
Dopamine
alpha-methyl-para-tyrosine and cocaine challenge, 181
Alzheimer's disease and, 1016
amperozide receptor binding and, 247
D4-like sites, schizophrenia and, 648
DAT1 dopamine transporter gene polymorphism, novelty seeking and, 1070
hippocampal receptor mRNA, regulation of, 155
lorazepam with ECT for catatonia and, 375
obsessive-compulsive disorder and, 889
reward dependence and monoamines, 275
ritanserin for cocaine dependence and, 932
uptake blockers, modafinil and, 1181
Dopamine hypothesis
of schizophrenia, moving beyond, 771
Dorsal brain systems
gender differences in schizophrenia and, 104
Dorsal periaqueductal grey area
CCK-4 in panic-like reactions and, 335
Double-blind studies
CCK-4 effects on respiratory resistance and, 206
controlled augmentation trials in schizophrenia and, 138
cranial electrostimulation therapy in smoking cessation and, 116
heterogeneity of serotonergic response in schizophrenia and, 6
nortriptyline and EEG sleep in elderly, 560
repeated *d*-amphetamine challenge in first-episode psychosis and, 749
Down-regulation
G protein density in major depression and, 704
hippocampal dopamine receptor mRNA regulation and, 155
Drug dependence
cranial electrostimulation therapy in smoking cessation and, 116
DSM-III-R test
for infantile autism, celiac disease and, 72
Dyspnea
CCK-4 effects on respiratory resistance and, 206
Dysthymia
P300 amplitude and, 740

Early gene expression
sensitization with clozapine and, 771
Early-onset psychosis
N400 in late-life schizophrenia and, 13
Eating
CSF CRH in eucortisolemic depression and, 166
Education level
basal ganglia volume in trichotillomania and, 39
gray matter volume and depression severity, 79
Effective radius
entorhinal cortex in schizophrenia and, 639
Elderly
apolipoprotein E polymorphism in a population sample age 75 +, 898
depression in, 925
major depression in, sleep EEG and, 560
N400 in late-life schizophrenia and, 13
Electrical asymmetries
brain, cognitive task performance in depression and, 1039
Electroconvulsive therapy (ECT)
behavioral effects and, 920
biochemical effects and, 920
circadian amplitude and, 1130
core body temperature and, 1130
depression and, 1130
lorazepam with, catatonia and, 375
sleep-onset rapid eye movement after, 191
Electrodermal activity
hyperthyroidism and, 1024
Electroencephalogram (EEG)
clozapine-induced changes in, 132
coherence, schizophrenia and, 655
electrical asymmetries during cognitive task performance in

depression and, 1039
laterality, temporal lobe epilepsy and, 617
sleep, depressive symptoms and, 904
sleep, nortriptyline and, 560
sleep, scopolamine in depressed adolescents and, 577
Electron microscopy
platelets in depression and, 965
Electrophysiology
amperozide receptor binding and, 247
electrical asymmetries during cognitive task performance in depression and, 1038
memory impairment in alcoholics and, 1157
mnemonic demand and, 1073
Electroretinogram
reduced, cocaine withdrawal and, 631
Emotional awareness
alexithymia and, 834
Empathy
SPECT study in psychopaths and, 96
Endogenous depression
ECT and tryptophan metabolism in, 201
Endomagnesium antibodies
autism and celiac disease, 72
End-tidal CO_2
panic disorder and, 982
Energy metabolism
mtDNA deletion in bipolar disorder and, 871
Entorhinal cortex
hippocampal dopamine receptor mRNA regulation and, 155
Environmental stressors
first night effect in depression and, 267
Epidemiology
apolipoprotein E polymorphism in a population sample age 75 +, 898
asthma and panic attacks, 625
Epilepsy
drug-resistant, autism and celiac disease, 72
temporal lobe, sexual behavior and EEG laterality in, 617
Epinephrine
adenylyl cyclase-coupled receptors in major depression and, 859
reward dependence and monoamines, 275
Erratum, 638
Ethics
psychiatric symptom-provoking studies and, 402
Ethnicity
platelet factor 4 and β-thromboglobulin with ischemic heart disease in depression, 290
Event-related potentials (ERPs)
Alzheimer's disease and, 1172
dysthymia and, 740
frontal cortex effects of chronic cocaine dependence and, 472
linguistic, schizophrenia and, 596
methylphenidate and, 434
mismatch negativity in Alzheimer's disease and, 382
N400 in late-life schizophrenia and, 13
to tone stimuli, PTSD and, 1006
workers with ongoing occupational exposure and, 854
Excretion patterns
reward dependence and monoamines, 275
Executive functions
schizophrenia and, 104, 816
Expansion
trinucleotide repeat, 756, 876
Explicit memory
schizophrenia and, 1087
Extrapyramidal symptoms
concomitant paroxetine/sumatriptan use and, clozapine treatment of, 144
quetiapine in schizophrenia and, 233
Eye-blink rate
repeated *d*-amphetamine challenge in first-episode psychosis and, 749
Eye tracking disorder
schizophrenia and, 781, 797

Factor structure
symptoms in functional psychoses and, 806
Family history
asthma and panic attacks, 625
EEG coherence in schizophrenia and, 655
exclusion of five trinucleotide repeat (CAG and CCG) expansion in schizophrenia and, 756
familial Alzheimer's disease pedigree and, 1172
leukocyte mtDNA deletion in affective disorders and, 311
lithium therapy and affective disorders, 425
panic disorder with familial bipolar disorder, 90
pericentromeric region of chromosome 18 in Irish pedigrees in bipolar disorder and, 486
structural brain abnormalities in schizophrenia and, 1080
Fasting
CSF CRH in eucortisolemic depression and, 166
FASTLINK
Tourette's syndrome and, 941
Fear
darkness and acoustic startle reflex, 453
light enhancement of acoustic startle reflex and, 461
Fenfluramine
prolactin response to, plasma tryptophan levels and, 416
serotonergic function in borderline personality disorder and, 737
serotonergic function in OCD and, 175
serotonin and fluoxetine, 546
Fever
clozapine effects on sleep and, 260
FG5620
amperozide receptor binding and, 247
Finger tapping speed
schizophrenia and, 797
First-degree relatives
lithium therapy history of affective disorders, 425
First night effect
depression and, 267
Five trinucleotide repeat expansion

CAG and CCG, exclusion of in schizophrenia, 756
Flesinoxan
depression and, 959
Flight behavior
CCK-4 in panic-like reactions and, 335
Flow volume loop
CCK-4 effects on respiratory resistance and, 206
Fluid regulation
schizophrenia and, 1097
Fluoride ions
forskolin-stimulated platelet adenylyl cyclase in major depression and, 30
Fluoxetine
gray matter volume and depression severity, 79
major depressive subtypes and treatment response, 568
serotonin and, 546
Fluvoxamine
serotonergic function in OCD and, 175
Forced respiration test
CCK-4 and, 206
Forced swimming test
behavioral and biochemical effects, 920
Forskolin
adenylyl cyclase-coupled receptors in major depression and, 859
platelet adenylyl cyclase in major depression and, 30
Frontal cortex
chronic cocaine dependence and, 472
neuroanatomy of anxiety and, 446
serotonin in schizophrenia and, 529
Frontal lobe
mismatch negativity in Alzheimer's disease and, 382
Frontal pole
in vitro ^{1}H-magnetic resonance spectroscopy in schizophrenia and, 359

Gα subunit
G protein density in major depression and, 704
Gabapentin
bipolar disorder and, 851
Gamma-aminobutyric acid (GABA)
amperozide receptor binding and, 247
lorazepam with ECT for catatonia and, 375
modafinil and, 1181
Tourette's syndrome and, 941
Gender
auditory evoked magnetic fields in left hemisphere in schizophrenia and, 609
autism and celiac disease, 72
basal ganglia volume in trichotillomania and, 39
first night effect in depression and, 267
forskolin-stimulated platelet adenylyl cyclase in major depression and, 30
gray matter volume and depression severity, 79
IL-1β in PTSD and, 345
major depression and cardiac autonomic control, 914
neuroleptic correlates of response production and, 57
obsessive-compulsive disorder and, 889, 976
OCD following globus pallidus infarction and, 410
olfactory identification and Wisconsin Card Sorting performance in schizophrenia, 104
PET of murderers and, 495
platelet factor 4 and β-thromboglobulin with ischemic heart disease in depression, 290
progesterone and adolescent suicidality, 956
reward dependence and monoamines, 275
serotonin function in borderline personality disorder and, 737
temporal lobe epilepsy and, 617
Genes
apolipoprotein E polymorphism in a population sample age 75 +, 898
apolipoprotein E4 in schizophrenia and, 296
CAG/CTG repeats in bipolar disorder and, 876
catechol-*o*-methyltransferase, affective disorders and, 282
DAT1 dopamine transporter, polymorphisms and, 1070
familial Alzheimer's disease and, 1172
immediate early, desipramine and, 317
panic disorder with familial bipolar disorder and, 90
pericentromeric region of chromosome 18 in Irish pedigrees in bipolar disorder and, 486
quadruplets with schizophrenia and-corr, 1185
sensitization with clozapine and, 771
serotonin transporter, schizophrenia and, 634
structural brain abnormalities in schizophrenia and, 1080
Tourette's syndrome and, 941
Gliadin antibodies
autism and celiac disease, 72
Globus pallidus
infarction, OCD following, 410
Glucose
metabolism, PET of murderers and, 495
prophylaxis, learned helplessness and, 324
Glutamate
in vitro ^{1}H-magnetic resonance spectroscopy in schizophrenia and, 359
Gluten
dietary, learning to attend to redundant stimuli and, 1060
Glycine receptor
Tourette's syndrome and, 941
Goal-directed behavior
schizophrenia and, 816
Go/no go
neuroleptic correlates of response production and, 57
G proteins
forskolin-stimulated platelet adenylyl cyclase in major depression and, 30
lithium and, 697
in major depression, density of, 704
platelet adenosine 5'-diphosphate ribosylation in bipolar disorder and, 413
Gray matter
auditory evoked magnetic fields in left hemisphere in schizophrenia and, 609
repeat ^{1}H-MRS in social phobia and, 419

Growth hormone (GH)
depression and, 827
obsessive-compulsive disorder and, 889
sumatriptan in SAD and, 24
Growth hormone-releasing hormone (GHRH)
obsessive-compulsive disorder and, 889
Guanine nucleotides (Gpp(NH)p)
forskolin-stimulated platelet adenylyl cyclase in major depression and, 30
Guanosine triphosphatase
receptor/G protein coupling and, 697
Guilt
SPECT study in psychopaths and, 96

Habituation
hyperthyroidism and, 1023
light enhancement of acoustic startle reflex and, 461
N40 amplitude and, 1051
Hair pulling
repetitive, basal ganglia volume in trichotillomania and, 39
Haloperidol
hippocampal dopamine receptor mRNA regulation and, 155
schizophrenia and, 585
Hamilton Depression Rating Scale
gray matter volume and depression severity, 79
major depressive subtypes and treatment response, 568
pyridostigmine/growth hormone challenge in depression and, 827
sleep EEG variables and, 904
Handedness
basal ganglia volume in trichotillomania and, 39
neuroanatomy of anxiety and, 446
schizophrenia and, 797
Harm avoidance
reward dependence and monoamines, 275
Tridimensional Personality Questionnaire and, 959
Heart rate
alpha-methyl-para-tyrosine and cocaine challenge, 181
CCK-4 effects on respiratory resistance and, 206
major depression and cardiac autonomic control, 914
Helplessness
glucose prophylaxis and, 324
Hemangioma
pontine vascular depression in depression and, 519
Hemispheric laterality
temporal lobe epilepsy and, 617
Heterogeneity
genetic, panic disorder with familial bipolar disorder, 90
Heterologous desensitization
adenylyl cyclase-coupled receptors in major depression and, 859
"High"
alpha-methyl-para-tyrosine and cocaine challenge, 181
High-performance liquid chromatography
salsolinol in parkinsonian CSF and, 514
Hippocampus
desipramine in immediate early gene expression and, 317
dopamine receptor mRNA, regulation of, 155
schizophrenia and, 585, 767, 1086
Histaminergic receptors
amperozide receptor binding and, 247
D,L-Homocysteic acid
CCK-4 in panic-like reactions and, 335
Homovanillic acid (HVA)
alpha-methyl-para-tyrosine and cocaine challenge, 181
behavioral symptoms in dementia and, 1016
MHPG and, 821
reward dependence and monoamines, 275
salsolinol in parkinsonian CSF and, 514
Hostile depression
treatment response and, 568
Hostility factor
heterogeneity of serotonergic response in schizophrenia and, 6
5-HTID receptor agonist
growth hormone response to sumatriptan in SAD and, 24
5-Hydroxyindoleacetic -acid (5-HIAA)
reward dependence and monoamines, 275
5-Hydroxytryptamine (5-HT)
amperozide receptor binding and, 247
ECT and tryptophan metabolism in depression, 201
heterogeneity of serotonergic response in schizophrenia and, 6
quetiapine in schizophrenia and, 233
Hypercortisolemia
Alzheimer's disease and, 1029
Hyperekplexia
Tourette's syndrome and, 941
Hypersensitivity
central serotonergic, schizophrenia and, 6
Hyperthyroidism
without depression, electrodermal activity and, 1024
Hyperventilation
panic disorder and, 982
Hypophyseal-pituitary-adrenal axis
Alzheimer's disease and, 1029
Hyposmolality
polydipsia-hyponatremia in schizophrenia and, 733, 767
Hypothalamic-pituitary-adrenal (HPA) axis
adenylyl cyclase-coupled receptors in major depression and, 859
corticotropin-releasing hormone and, 882
IL-1β in PTSD and, 345
Klein-Levin syndrome and, 299
sustained remission in major depression and, 85
Hypothalamic-pituitary-thyroid (HPT) axis
hyperthyroidism without depression and, 1024

ICI 202,636
quetiapine in schizophrenia and, 233
Idiom recognition task
linguistic ERPs in schizophrenia and, 596
Ignore conditions
mismatch negativity in Alzheimer's disease and, 382
Illumination
enhancement of acoustic startle reflex and, 461

Imipramine
G protein density in major depression and, 704
noradrenergic cerebral cortex axons and, 687
Immediate early gene
expression, desipramine and, 317
Immune response
CSF CRH in eucortisolemic depression and, 166
zinc serum level in major depression and, 349
Imprinting
schizophrenia and, 760
Impulsivity
serotonin and conduct disorder in adolescents, 553
Induction
desipramine in immediate early gene expression and, 317
Inescapable shock
glucose prophylaxis and learned helplessness, 324
Infants
autism and celiac disease, 72
Inflammatory response
zinc serum level in major depression and, 349
Information processing
event-related potentials in OCD and, 46
linguistic ERPs in schizophrenia and, 596
methylphenidate and, 434
neuroleptic correlates of response production and, 57
Inhalation
deep, cotinine levels in schizophrenic smokers and, 1
Inhibition
alpha-methyl-para-tyrosine and cocaine challenge, 181
N40 amplitude and, 1050
neuroleptic correlates of response production and, 57
In situ hybridization
hippocampal dopamine receptor mRNA regulation and, 155
Insular cortex
neuroanatomy of anxiety and, 446
Interleukin 1β (IL-1β)
obsessive-compulsive disorder and, 976
posttraumatic stress disorder and, 345
Intimidation
SPECT study in psychopaths and, 96
Irish pedigrees
pericentromeric region of chromosome 18 in bipolar disorder and, 486
Irritability
serotonin and fluoxetine, 546
Ischemic heart disease
depression with, platelet factor 4 and β-thromboglobulin in, 290
Isoproterenol
adenylyl cyclase-coupled receptors in major depression and, 859

Jejunal biopsy
autism and celiac disease, 72
Jerks
myoclonic, sensitization with clozapine and, 771
Juvenile offenders
serotonin and conduct disorder in adolescents, 553

K^+ channels
lactate-induced panic attacks in alcoholism and, 992
Ketamine
NMDA-induced psychosis and, 664
Kindling
sensitization with clozapine and, 771
Kleine-Levin syndrome
HPA axis and, 299

Lactate
panic attacks induced by, alcoholism and, 992
Language
ERPs in schizophrenia and, 596
N400 in late-life schizophrenia and, 13
Late-onset depression
subcortical hyperintensities in, 367
Late-onset psychosis
N400 and, 13
Latency
auditory evoked magnetic fields in left hemisphere in schizophrenia and, 609
event-related potentials in OCD and, 46
first night effect in depression and, 267
N400 in late-life schizophrenia and, 13
neuroleptic correlates of response production and, 57
REM sleep disinhibition at sleep onset and, 713
Laterality
electrical asymmetries during cognitive task performance in depression and, 1039
L-dopa
salsolinol in parkinsonian CSF and, 514
Learned helplessness
glucose prophylaxis and, 324
Learning
dietary gluten and, 1059
sialic acid reactivity and mental retardation, 68
Left angular gyrus
PET of murderers and, 495
Left cerebral hemisphere
event-related potentials in OCD and, 46
PET of murderers and, 495
schizophrenia and, 585
Lenticulate nuclei
neuroanatomy of anxiety and, 446
Letters
of alphabet, neuroleptic correlates of response production and, 57
Leukocytes
adenylyl cyclase-coupled receptors in major depression and, 859
mtDNA deletion, affective disorders and, 311
Lever press
dietary gluten and, 1060
Lewis-X
sialic acid reactivity and mental retardation, 68
Lewy body varient
of Alzheimer's disease, 527-corr
Libido

temporal lobe epilepsy and, 617
Light therapy
growth hormone response to sumatriptan in SAD and, 24
melatonin suppression in SAD and, 509
seasonal affective disorder and, 1000
seasonal variation in core temperature and, 122
Limbic system
neuroanatomy of anxiety and, 446
Linguistic information processing
schizophrenia and, 596
Linkage analysis
pericentromeric region of chromosome 18 in Irish pedigrees in bipolar disorder and, 486
Tourette's syndrome and, 941
Literal phrases
linguistic ERPs in schizophrenia and, 596
Lithium
for affective disorders, family history correlated with response to, 425
mania remitted by, acute tryptophan depletion and, 1076
platelet adenosine 5'-diphosphate ribosylation in bipolar disorder and, 413
receptor/G protein coupling and, 697
Longitudinal studies
clozapine effects on sleep and, 260
subcortical hyperintensities in major depression and, 367
Long-term stress
noradrenergic cerebral cortex axons and, 687
Lorazepam
ECT with, catatonia and, 375
Lumbar puncture
CSF CRH in eucortisolemic depression and, 166
Lymphocytes
volume regulation, polydipsia-hyponatremia in schizophrenia and, 733

Magnetic resonance imaging (MRI)
basal ganglia volume in trichotillomania and, 39
gray matter volume and depression severity, 79
schizophrenia and, 609, 767, 816, 1087
subcortical hyperintensities in major depression and, 367
Magnetic resonance spectroscopy (MRS)
cocaine abstinence and, 1105
in vivo, of Alzheimer's disease in parietal and temporal lobes, 147
in vitro, schizophrenia and, 359
repeat, social phobia and, 419
Magnetoencephalography
auditory evoked magnetic fields in left hemisphere in schizophrenia and, 609
Major depression
adenylyl cyclase-coupled receptors in, 859
cardiac autonomic contol in, 914
CCK-4-induced calcium mobilization in T cells in, 151
CSF CRH in, 166
forskolin-stimulated platelet adenylyl cyclase in, 30
gray matter volume in, 79
hypothalamic-pituitary-adrenal predictors of remission in, 85
OCD following globus pallidus infarction and, 410
platelet G protein density in, 704
pyridostigmine/growth hormone challenge in, 827
sleep EEG in, 560, 904
sleep-onset rapid eye movement after ECT in, 191
subcortical hyperintensities in, 367
subtypes, treatment response and, 568
zinc serum level in, 349
Mania
Altman self-rating mania scale in, 948
factor structure symptoms in, 806
gabapentin in, 851
lithium-remitted, acute tryptophan depletion and, 1076
thyroid function tests in, 302
Manic depressive disorder
pericentromeric region of chromosome 18 in Irish pedigrees in, 486
Marijuana
progesterone and adolescent suicidality, 956
Maternal inheritance
psychiatric symptoms in diabetes and, 1067
Medication washout
heterogeneity of serotonergic response in schizophrenia and, 6
Melancholic depression
cardiac autonomic contol in, 914
treatment response and, 568
MELAS
mitochondria and, 1067
Melatonin
suppression, by bright light in SAD, 509
Membranes
brain, receptor/G protein coupling and, 697
Memory
alcoholism and, 1157
calpain-calpastatin system in schizophrenia and, 228
DHEA and, 845
schizophrenia and, 1087
Mental retardation
sialic acid reactivity of sugar chain structure Lewis X in, 68
Mesocortex
amperozide receptor binding and, 247
Messenger RNA (mRNA)
hippocampal dopamine receptor, antipsychotic regulation of, 155
sensitization with clozapine and, 771
serotonin transporter, antidepressants and, 1177
Metabolism
brain, glucose prophylaxis and learned helplessness, 324
brain, in vitro ^{1}H-magnetic resonance spectroscopy in schizophrenia and, 359
brain, salsolinol in parkinsonian CSF and, 514
CSF CRH in eucortisolemic depression and, 166
energy, mtDNA deletion in bipolar disorder and, 871
glucose, PET of murderers and, 495

tryptophan, ECT in depression and, 201
Metanephrine
reward dependence and monoamines, 275
3-Methoxy 4 hydroxyphenylglycol (MHPG)
alpha-methyl-para-tyrosine and cocaine challenge, 181
homovanillic acid and, 821
reward dependence and monoamines, 275
3-*O*-Methyldopa
salsolinol in parkinsonian CSF and, 514
Methylphenidate
electrophysiological indices of information processing and, 434
Microsatellite markers
pericentromeric region of chromosome 18 in Irish pedigrees in bipolar disorder and, 486
Tourette's syndrome and, 941
Microsequencing
apolipoprotein E polymorphism in a population sample age 75 +, 898
MIDD
mitochondria and, 1067
Migration
entorhinal cortex in schizophrenia and, 639
Minute ventilation
panic disorder and, 982
Mismatch negativity
Alzheimer's disease and, 382
methylphenidate and ERP components, 434
"Miswiring"
entorhinal cortex in schizophrenia and, 639
Mitochondrial DNA (mtDNA)
deletion, affective disorders and, 311
deletion, bipolar disorder and, 871
point mutation in, psychiatric symptoms in diabetes and, 1066
Mitochondrial transfer $RNA^{Leu(UUR)}$ mutation
at position 3243, mental disorders in diabetics and, 524
Mixture analysis
eye tracking disorder in schizophrenia and, 781
Mnemonic demand
electrophysiologic responses to, 1073
Moclobemide
DST and, 925
Modafinil
overview, 1181
Modified Scale for the Assessment of Negative Symptoms
quetiapine in schizophrenia and, 233
Molecular genetics
mtDNA deletion in bipolar disorder and, 871
Monoamines
amperozide receptor binding and, 247
reward dependence and, 275
Mononuclear leukocytes
adenylyl cyclase-coupled receptors in major depression and, 859
Mood disorders
depressive symptoms related to sleep EEG variables in, 904
factor structure symptoms in, 806
leukocyte mtDNA deletion in, 311
Morphometry
basal ganglia volume in trichotillomania and, 39
gray matter volume and depression severity, 79
schizophrenia and, 1087
Motor defects
ocular, schizophrenia and, 781, 797
lorazepam with ECT for catatonia and, 375
Multicenter trial
depression and, 925
Multipoint maps
Tourette's syndrome and, 941
Multivariate analysis of variance
autism and, 1148
factor structure symptoms in functional psychoses and, 806
Murderers
brain abnormalities in, 495
Muscarinic receptors
amperozide receptor binding and, 247
Mutation
mtDNA deletion in bipolar disorder and, 871
myo-inositol
cocaine abstinence and, 1105
repeat ^{1}H-MRS in social phobia and, 419
Myocardial infarction
platelet factor 4 and β-thromboglobulin with ischemic heart disease in depression, 290
Myoclonus
sensitization with clozapine and, 771

N1 amplitude
event-related potentials in OCD and, 46
N2b amplitude
mismatch negativity in Alzheimer's disease and, 382
N40 amplitude
parametric study and, 1051
N100 amplitude
auditory evoked magnetic fields in left hemisphere in schizophrenia and, 609
N400 amplitude
late-life schizophrenia and, 13
linguistic ERPs in schizophrenia and, 596
N-acetyl aspartate
cocaine abstinence and, 1105
in vitro ^{1}H-magnetic resonance spectroscopy in schizophrenia and, 359
proton magnetic resonance spectroscopy of Alzheimer's disease in parietal and temporal lobes and, 147
repeat ^{1}H-MRS in social phobia and, 419
N-acetyl-β-glucosaminidase (NAG)
suicide attempts and, 286
Naltrexone
persistent analgesia in former opiate addicts, 962
Narcolepsy
REM sleep disinhibition at sleep onset and, 713
Nearest neighbor distances
entorhinal cortex in schizophrenia and, 639

Negative symptoms
factor structure symptoms in functional psychoses and, 806
schizophrenia and, 13, 233, 664, 760
Nemonapride
schizophrenia and, 648
Network
semantic, N400 in late-life schizophrenia and, 13
Neural circuit theory
of autism, 1138
Neuroanatomy
anxiety and, 446
Neurochemical alterations
cocaine and, 1105
Neuroimaging
schizophrenia and, 1087
Neuroleptics
Alzheimer's disease and, 1016
controlled augmentation trials in schizophrenia and, 138
correlates, response production and, 57
heterogeneity of serotonergic response in schizophrenia and, 6
Neurological disorders
autism and celiac disease, 72
olfactory dysfunction in, 721
Neurons
entorhinal cortex in schizophrenia and, 639
in vitro ^{1}H-magnetic resonance spectroscopy in schizophrenia and, 359
Neuropathology
cerebellum in schizophrenia and, 213
Neuropsychology
gender differences in schizophrenia and, 104
schizophrenia and, 1087
Neuroreceptor subunit genes
Tourette's syndrome and, 941
Neurovegetative symptoms
depressive symptoms related to sleep EEG variables, 904
News and Notes, 637
Nicotine
as confound in psychiatric studies, 1177
cotinine levels in schizophrenic smokers and, 1
Nighttime
clozapine effects on sleep and, 260
seasonal variation in core temperature and, 122
Nissl-stained neurons
entorhinal cortex in schizophrenia and, 639
N-methyl-D-aspartate (NMDA) receptor
psychosis induced by, 664
No go trials
neuroleptic correlates of response production and, 57
Non-rapid eye movement (NREM)
clozapine effects on sleep and, 260
Nonsense phrases
linguistic ERPs in schizophrenia and, 596
Norepinephrine
adenylyl cyclase-coupled receptors in major depression and, 859
alpha-methyl-para-tyrosine and cocaine challenge, 181
ECT and, 920
reward dependence and monoamines, 275
transcranial magnetic stimulation and, 920
Normetanephrine
reward dependence and monoamines, 275
Nortriptyline
DST and, 925
"Not guilty by reason of insanity"
plea of, PET of murderers and, 495
Novelty seeking
DAT1 dopamine transporter gene polymorphism and, 1070
reward dependence and monoamines, 275

Obsessive-compulsive disorder (OCD)
basal ganglia volume in trichotillomania and, 39
calpain-calpastatin system and, 228
cytokines and, 1186-corr
dopamine function in, 889
event-related potentials in, 46
following bilateral globus pallidus infarction, 410
interleukin 1β and, 976
neuroanatomy of anxiety and, 446
serotonergic function in, 175
tumor necrosis factor in, 976
symptom provocation in, 969
Occupational exposure
ongoing, ERPs in workers with, 854
Ocular motor defects
schizophrenia and, 781, 797
Oddball paradigm
event-related potentials in OCD and, 46
methylphenidate and ERP components, 434
mismatch negativity in Alzheimer's disease and, 382
posttraumatic stress disorder and, 1006
Olfactory dysfunction
gender differences in schizophrenia and, 104
psychiatric disorders and, 721
Operation Desert Storm returnees
salivary cortisol levels in, 849
Opiate receptors
amperozide receptor binding and, 247
Opioids
endogenous, persistent analgesia in former opiate addicts, 962
Orbitofrontal cortex
neuroanatomy of anxiety and, 446
Organic solvents
ERPs in workers with ongoing occupational exposure, 854
Overt Aggression Scale
serotonin and fluoxetine, 546

P2 amplitude
event-related potentials in OCD and, 46
P3 amplitude
methylphenidate and ERP components, 434
mismatch negativity in Alzheimer's disease and, 382
posttraumatic stress disorder and, 1006

P3A amplitude
chronic cocaine dependence and, 472
P300 amplitude
dysthymia and, 740
ERPs in workers with ongoing occupational exposure, 854
linguistic ERPs in schizophrenia and, 596
neuroleptic correlates of response production and, 57
Pain sensitivity
persistent analgesia in former opiate addicts, 962
Painters
ERPs in workers with ongoing occupational exposure, 854
Panic attacks/disorder
antipanic treatment effect on response to carbon dioxide, 982
anxiogenic effects of pentagastrin in social phobia and, 76
asthma and panic attacks, 625
CCK-4 effects on respiratory resistance and, 206
CCK-4-induced calcium mobilization in T cells in, 151
CCK-4 in panic-like reactions and, 335
familial bipolar disorder with, 90
lactate-induced panic attacks in, alcoholism and, 992
mitochondrial transfer $RNA^{Leu(UUR)}$ mutation in diabetes and, 524
pyridostigmine/growth hormone challenge in depression and, 827
Panic-like reactions
CCK-4 and, 335
Paralimbic belt
neuroanatomy of anxiety and, 446
Parallel down-regulation
hippocampal dopamine receptor mRNA regulation and, 155
Parallel trials
controlled augmentation trials in schizophrenia and, 138
Parametric study
N40 auditory evoked response and, 1051
Parietal cortex
serotonin in schizophrenia and, 529
Parietal lobe
proton magnetic resonance spectroscopy of Alzheimer's disease and, 147
Parkinson's disease
salsolinol CSF levels and, 514
Paroxetine
amperozide receptor binding and, 247
concomitant sumatriptan use and paroxysmal dyskinesia, 144
Paroxysmal dyskinesia
concomitant paroxetine/sumatriptan use and, clozapine treatment of, 144
Passive switching
mismatch negativity in Alzheimer's disease and, 382
Pathophysiology
growth hormone response to sumatriptan in SAD and, 24
leukocyte mtDNA deletion in affective disorders and, 311
Pedigrees
CAG/CTG repeats in bipolar disorder and, 876
familial Alzheimer's disease, 1172
pericentromeric region of chromosome 18 in bipolar disorder and, 486
Pentagastrin
angiogenic effects of, social phobia and, 76
Pericentromeric region
of chromosome 18 in Irish pedigrees, bipolar disorder and, 486
Personality dimension
reward dependence and monoamines, 275
Personality disorders
comorbid, depression and, 568
serotonin and fluoxetine, 546
Tridimensional Personality Questionnaire and, 959
Phenotypic marker
for alcoholism, neuroleptic correlates of response production and, 57
Phobia
neuroanatomy of anxiety and, 446
Phototherapy
growth hormone response to sumatriptan in SAD and, 24
melatonin suppression in SAD and, 509
seasonal affective disorder and, 1000
seasonal variation in core temperature and, 122
Pimozide
augmentation, schizophrenia and, 522
Placebo
alpha-methyl-para-tyrosine and cocaine challenge, 181
CCK-4 effects on respiratory resistance and, 206
controlled augmentation trials in schizophrenia and, 138
DST and, 925
heterogeneity of serotonergic response in schizophrenia and, 6
methylphenidate and ERP components, 434
nortriptyline and EEG sleep in elderly, 560
quetiapine in schizophrenia and, 233
repeated *d*-amphetamine challenge in first-episode psychosis and, 749
serotonergic function in OCD and, 175
serotonin and fluoxetine, 546
Plasma level
alpha-methyl-para-tyrosine and cocaine challenge, 181
clozapine-induced EEG changes and, 132
CSF CRH in eucortisolemic depression and, 166
homovanillic acid, behavioral symptoms in dementia and, 1016
interleukin 1β, OCD and, 976
MHPG/homovanillic acid, 821
nortriptyline and EEG sleep in elderly, 560
serotonergic function in OCD and, 175
tryptophan, prolactin response to fenfluramine and, 416
tumor necrosis factor, OCS and, 976
Platelet-derived growth factor BB (PDGF-BB) homodimer
sialic acid reactivity and mental retardation, 68
Platelet factor 4
β-thromboglobulin and, in depressed patients with ischemic heart disease, 290
Platelet(s)

adenosine 5'-diphosphate, ribosylation in bipolar disorder and, 413
adenylyl cyclase, forskolin-stimulated activity in major depression and, 30
depression and, 965
G protein density in major depression and, 704
receptor/G protein coupling and, 697
serotonin, adolsecents with conduct disorder and, 553
sialic acid reactivity and mental retardation, 68
Point mutation
in mtDNA, psychiatric symptoms in diabetes and, 1067
Polydypsia-hyponatremia
comparison of prevalence, 1097
schizophrenia and, 767
Polymerase chain reaction (PCR)
exclusion of five trinucleotide repeat (CAG and CCG) expansion in schizophrenia and, 756
leukocyte mtDNA deletion in affective disorders and, 311
mtDNA deletion in bipolar disorder and, 871
Tourette's syndrome and, 941
Polymorphisms
apolipoprotein E, in a population sample age 75 +, 898
CAG/CTG repeats in bipolar disorder and, 876
DAT1 dopamine transporter gene, novelty seeking and, 1070
exclusion of five trinucleotide repeat (CAG and CCG) expansion in schizophrenia and, 756
serotonin transporter gene, schizophrenia and, 634
Polysomnography
clozapine effects on sleep and, 260
depressive symptoms related to sleep EEG variables, 904
first night effect in depression and, 267
sleep-onset rapid eye movement after ECT and, 191
Polyuria
schizophrenia and, 1097
Pontine vascular malformation
depression and, 519
Positive symptoms
factor structure symptoms in functional psychoses and, 806
NMDA-induced psychosis and, 664
schizophrenia and, 233, 760
Positron emission tomography (PET)
alexithymia and, 834
brain abnormalities in murderers and, 495
neuroanatomy of anxiety and, 446
Posterior superior temporal gyrus
auditory evoked magnetic fields in left hemisphere in schizophrenia and, 609
Postmortem analysis
schizophrenia and, 296, 359, 529, 639, 648
Poststress period
glucose prophylaxis and learned helplessness, 324
Postsynaptic agonist
heterogeneity of serotonergic response in schizophrenia and, 6
Posttraumatic stress disorder (PTSD)
combat-related, auditory event-related potentials to tone stimuli and, 1005
combat-related, interleukin 1β and, 345
combat-related, salivary cortisol in, 849
dexamethasone suppression in adult women traumatized by childhood sexual abuse and, 680
neuroanatomy of anxiety and, 446
Prefrontal brain systems
gender differences in schizophrenia and, 104
Prefrontal cortex
PET of murderers and, 495
serotonin in schizophrenia and, 529
Preoperative stress
ECT and tryptophan metabolism in depression, 201
Prepulse inhibition
darkness and acoustic startle reflex, 453
Presenilin 1 mutation
familial Alzheimer's disease, 1172
Primate aggression
serotonin and, social dominance as confounding factor in studies of, 305-corr, 306-corr (response)
Principal-component analysis
factor structure symptoms in functional psychoses and, 806
Probands
CAG/CTG repeats in bipolar disorder and, 876
Progesterone
adolescent suicidality and, 956
Prolactin
heterogeneity of serotonergic response in schizophrenia and, 6
obsessive-compulsive disorder and, 889
response to fenfluramine, plasma tryptophan levels and, 416
serotonergic function in OCD and, 175
serotonin and fluoxetine, 546
serotonin function in borderline personality disorder and, 737
Prospective study
apolipoprotein E4 in schizophrenia and, 296
Prostaglandins
adenylyl cyclase-coupled receptors in major depression and, 859
Proton magnetic resonance spectroscopy
cocaine abstinence and, 1105
in vivo, of Alzheimer's disease in parietal and temporal lobes, 147
repeat, social phobia and, 419
Pruning
neuronal, entorhinal cortex in schizophrenia and, 639
Psychopathology
glucose prophylaxis and learned helplessness, 324
heterogeneity of serotonergic response in schizophrenia and, 6
Psychopaths
SPECT study os semantic and affective processing in, 96
Psychophysiology
event-related potentials in OCD and, 46
N400 in late-life schizophrenia and, 13

Psychoses
factor structure of symptoms in, 806
first-episode, repeated *d*-amphetamine challenge in, 749
NMDA-induced, blunting and, 664
related, N400 in late-life schizophrenia and, 13
Psychotropic drugs
posttraumatic stress disorder and, 1005
Pyridostigmine/growth hormone challenge
depression and, 827

Quadruplets
schizophrenic, 1186-corr
Quantitative imaging
gray matter volume and depression severity, 79
leukocyte mtDNA deletion in affective disorders and, 311
Quetiapine
schizophrenia and, 233

Raclopride
schizophrenia and, 648
Raphe nuclei
pontine vascular depression in depression and, 519
serotonin transporter mRNA and, 1072
Rapid eye movement (REM)
clozapine effects on sleep and, 260
first night effect in depression and, 267
Lewy body variant of Alzheimer's disease and, 527-corr
sleep in depressed adolescents and, 577
sleep-onset, after ECT, 191
sleep-onset, disinhibition at, 713
Rebreathing
panic disorder and, 982
Recent/remote memory dissociation
schizophrenia and, 585
Receptor/G protein coupling
lithium and, 697
Receptors
adenylyl cyclase-coupled, major depression and, 859
α-7 nicotinic,cotinine levels in schizophrenic smokers and, 1
amperozide, 247
G protein density in major depression and, 704
hippocampal dopamine, receptor mRNA regulation and, 155
5-HTID, growth hormone response to sumatriptan in SAD and, 24
IL-1β in PTSD and, 345
NMDA-induced psychosis and, 664
serotonergic, heterogeneity of serotonergic response in schizophrenia and, 6
Tourette's syndrome and, 941
Rectal temperature
clozapine effects on sleep and, 260
Redundant stimuli
dietary gluten and, 1059
Remission
hypothalamic-pituitary-adrenal predictors of, depression and, 85
seasonal variation in core temperature and, 122
Remorse
SPECT study in psychopaths and, 96
Repeat expansion detection
CAG/CTG repeats in bipolar disorder and, 876
schizophrenia and, 756
Repetitive behaviors
basal ganglia volume in trichotillomania and, 39
schizophrenia and, 1097
Replication
reduced blue cone electroretinogram in cocaine withdrawal and, 631
Respiration
asthma and panic attacks, 625
panic disorder and, 982
Respiratory resistance
CCK-4 and, 206
Respiratory sinus srrhythmia
major depression and cardiac autonomic control, 914
Response production
neuroleptic corrrelates of, 57
Retrospective rating scales
darkness and acoustic startle reflex, 453
Reward dependence
monoamines and, 275
Rey Auditory Verbal Learning Test
schizophrenia and, 797
Right cerebral hemisphere
event-related potentials in OCD and, 46
PET of murderers and, 495
Risk paramaters
for alcoholism, neuroleptic correlates of response production and, 57
subcortical hyperintensities in major depression and, 367
Ritanserin
cocaine dependence and, 932
Roof nuclei
cerebellum in schizophrenia and, 213
Rostral pons
pontine vascular depression in depression and, 519

Saccades
schizophrenia and, 781, 797
Salivary level
cortisol, PTSD and, 849
MHPG/homovanillic acid, 821
Salsolinol
parkinsonian CSF and, 514
Schizoaffective disorders
factor structure symptoms in, 806
Schizophrenia
anterior medial temporal lobe volume in polydypsia with or without hyposmolemia, 767
anticipation in, 760
apolipoprotein E4 in, 225, 296
CCK-4-induced calcium mobilization in T cells in, 151
cerebellum in, 213
clozapine effects on sleep in, 260

clozapine-induced EEG changes in, 132
controlled augmentation trials in, 138
cortical serotonergic system in, 529
cotinine levels in smokers in, 1
cytokines in, 308-corr, 308-corr (response)
delayed memory in, 1087
dietary gluten in, 1060
dopamine D4-like sites in, 648
entorhinal cortex in, 639
eye tracking disorder in, 781, 797
fluid regluation in, 1097
gender differences in olfactory identification and Wisconsin Card Sorting performance in, 104
hippocampal dopamine receptor mRNA regulation in, 155
hippocampus in, 585, 1087
imprinting in, 760
in vitro ^{1}H-magnetic resonance spectroscopy in, 359
late-life, N400 in, 13
linguistic event-related potentials in, 596
nemonapride in, 648
neuropsychological and oculomotor relationships in, 797
olfactory dysfunction in, 721
pimozide augmentation to clozapine in, 522
polydipsia-hyponatremia in, 733, 1097
pyridostigmine/growth hormone challenge in depression and, 827
quadruplets with, 1186-corr
quetiapine in, 233
raclopride in, 648
recent/remote memory dissociation in, 585
repeated *d*-amphetamine challenge in, 749
repetitive behaviors in, 1096
serotonin in, 6
spatial pattern pont analyses in, 639
striatal reduction in, 816
structural brain abnormalities in, 1080
temporal lobe in, 1087
treatment-refractory, heterogeneity of serotononin response in, 6
trinucleotide repeat and, 756, 760
Wisconsin Card Sorting Test in, 104, 797, 816
Schizophreniform disorders
factor structure symptoms in, 806
Seasonal affective disorder (SAD)
growth hormone response to sumatriptan in, 24
melatonin suppression by bright light in, 509
regional cerebral blood flow and, 1000
seasonal variation in core temperature regulation during sleep, 122
Sedation
clozapine effects on sleep and, 260
Segmentation
basal ganglia volume in trichotillomania and, 39
Seizures
clozapine-induced EEG changes and, 132
desipramine in immediate early gene expression and, 317
sensitization with clozapine and, 771
temporal lobe epilepsy and, 617
Self-administration
nicotine, cotinine levels in schizophrenic smokers and, 1
Semantic congruity
N400 in late-life schizophrenia and, 13
Semantic network
N400 in late-life schizophrenia and, 13
Semantic processing
SPECT study in psychopaths and, 96
Semiautomated intensity
well-characterized, basal ganglia volume in trichotillomania and, 39
Sensitization
clozapine and, 771
light enhancement of acoustic startle reflex and, 461
model, of psychosis, 749, 771
stimulant, in humans, 230-corr, 230-corr (response)
Sensory gating
lactate-induced panic attacks in alcoholism and, 992
N40 amplitude and, 1051
Sensory inhibition deficits
cotinine levels in schizophrenic smokers and, 1
Sensory memory
mismatch negativity in Alzheimer's disease and, 382
Seroquel
schizophrenia and, 233
Serotonin
amperozide receptor binding and, 247
borderline personality disorder and, 737
conduct disorder in adolescents and, 553
depression and, 959
ECT and tryptophan metabolism in depression, 201
fluoxetine and, 546
growth hormone response to sumatriptan in SAD and, 24
NAG and suicide attempts, 286
obsessive-compulsive disorder and, 175
pontine vascular depression in depression and, 519
primate aggression and, social dominance as confounding factor in studies of, 305-corr, 306-corr (response)
reward dependence and monoamines, 275
ritanserin for cocaine dependence and, 932
schizophrenia and, 529
transporter gene polymorphism, schizophrenia and, 634
transporter mRNA, antidepressants and, 1177
tryptophan depletion in lithium-remitted mania and, 1076
tryptophan levels and prolactin response to fenfluramine, 416
Serum level
alpha-methyl-para-tyrosine and cocaine challenge, 181
clozapine-induced EEG changes and, 132
IL-1β in PTSD and, 345
serotonin transporter mRNA and, 1072
Sexual abuse
childhood, dexamethasone suppression in adult women traumatized by, 680
Sexual behavior
temporal lobe epilepsy and, 617

Shock
glucose prophylaxis and learned helplessness, 324
Shuttle-escape performance
glucose prophylaxis and learned helplessness, 324
Sialic acid
reactivity, mental retardation and, 68
Siblings
EEG coherence in schizophrenia and, 655
Signal transduction
adenylyl cyclase-coupled receptors in major depression and, 859
desipramine in immediate early gene expression and, 317
G protein density in major depression and, 704
Single electroconvulsive therapy
tryptophan metabolism in depression and, 201
Single photon emission computed tomography (SPECT)
mitochondrial transfer $RNA^{Leu(UUR)}$ mutation in diabetes and, 524
semantic and affective processing in psychopaths and, 96
Skin blood flow
CCK-4 effects on respiratory resistance and, 206
Skin temperature
seasonal variation in core temperature and, 122
SLC6A4
serotonin transporter gene polymorphism and schizophrenia, 634
Sleep
clozapine and, 260
EEG, depressive symptoms and, 904
EEG, nortriptyline and, 560
EEG, scopolamine in depressed adolescents and, 577
first night effect in depression and, 267
Lewy body variant of Alzheimer's disease and, 527-corr
onset, rapid eye movement after ECT and, 191
REM, disinhibition at onset, 713
seasonal variation in core temperature and, 122
Sleep "drive"
depressive symptoms related to sleep EEG variables, 904
Sleepiness
clozapine-induced EEG changes and, 132
melatonin suppression in SAD and, 509
Slowing
clozapine-induced EEG changes and, 132
Slow vital capacity
CCK-4 effects on respiratory resistance and, 206
Slow-wave sleep
depressed adolescents and, 577
Smell identification
gender differences in schizophrenia and, 104
Smoking
cessation, cranial electrostimulation therapy and, 116
cotinine levels in schizophrenics and, 1
CSF CRH in eucortisolemic depression and, 166
Smooth pursuit
eye tracking disorder in schizophrenia and, 781
Social dominance
as confounding factor in studies of primate aggression and serotonin, 305-corr, 306-corr (response)
Social phobia
asthma and panic attacks, 625
pentagastrin anxiogenic effects in, 76
repeat proton magnetic resonance spectroscopy in, 419
Social skills
serotonin and conduct disorder in adolescents, 553
Somatomedin C
obsessive-compulsive disorder and, 889
Spatial pattern point analyses
entorhinal cortex in schizophrenia and, 639
Specific gravity
of urine, 1097
Spikes
clozapine-induced EEG changes and, 132
Spoken phrase
N400 in late-life schizophrenia and, 13
Stage 2 sleep
clozapine effects on sleep and, 260
Startle reactivity
darkness and, 453
light enhancement of, 461
Statistical power
controlled augmentation trials in schizophrenia and, 138
Stimulant sensitization
in humans, 230-corr, 230-corr (response)
Stress
Alzheimer's disease and, 1172
first night effect in depression and, 267
glucose prophylaxis and learned helplessness, 324
noradrenergic cerebral cortex axons and, 687
preoperative, ECT and tryptophan metabolism in depression, 201
Striatal reduction
schizophrenia and, 816
Striatum
amperozide receptor binding and, 247
hippocampal dopamine receptor mRNA regulation and, 155
modafinil and, 1181
Stroke
OCD following globus pallidus infarction and, 410
Subcortical brain processes
PET of murderers and, 495
Sucrose
glucose prophylaxis and learned helplessness, 324
Sugar chain structure Lewis X
sialic acid reactivity, mental retardation and, 68
Suicide
adolescent, progesterone and, 956
arginine vasopressin in depression and, 744
mtDNA deletion in bipolar disorder and, 871
N-acetyl-β-glucosaminidase and, 286
serotonin in schizophrenia and, 529
Sulci-to-brain ratio
structural brain abnormalities in schizophrenia and, 1080
Sumatriptan
concomitant paroxetine use and paroxysmal dyskinesia, 144

growth hormone response to, in SAD, 24
Summer
melatonin suppression in SAD and, 509
seasonal variation in core temperature and, 122
Superficial laminae
entorhinal cortex in schizophrenia and, 639
Superior parietal gyrus
PET of murderers and, 495
Surface energy
neuroleptic correlates of response production and, 57
Susceptibility gene
pericentromeric region of chromosome 18 in Irish pedigrees in bipolar disorder and, 486
Switching mechanism
attentional, mismatch negativity in Alzheimer's disease and, 382
Symptom provocation
ethics and, 402
neuroanatomy of anxiety and, 446
obsessive-compulsive disorder and, 969
Synaptic proteins
cerebellum in schizophrenia and, 213
Synergy
of lorazepam with ECT for catatonia, 375

Tachycardia
CCK-4 in panic-like reactions and, 335
Tailshocks
glucose prophylaxis and learned helplessness, 324
Target detection task
posttraumatic stress disorder and, 1006
Task-dependent processes
event-related potentials in OCD and, 46
T cells
CCK-4-induced calcium mobilization in, 151
zinc serum level in major depression and, 349
Temporal lobe
anterior medial volume, 767
epilepsy, sexual behavior and EEG laterality in, 617
hippocampal dopamine receptor mRNA regulation and, 155
PET of murderers and, 495
proton magnetic resonance spectroscopy of Alzheimer's disease and, 147
schizophrenia and, 585, 767, 1087
Thalamus
in vitro ^{1}H-magnetic resonance spectroscopy in schizophrenia and, 359
PET of murderers and, 495
Thermoregulation
seasonal variation in core temperature and, 122
β-Thromboglobulin
platelet factor 4 and, in depressed patients with ischemic heart disease, 290
Thrombosis
platelet factor 4 and β-thromboglobulin with ischemic heart disease in depression, 290
Thyroid function
electrodermal activity and, 1024
in first-episode bipolar disorder and mixed types, 302
Tics
Tourette's syndrome and, 941
Tobacco
cotinine levels in schizophrenics and, 1
CSF CRH in eucortisolemic depression and, 166
withdrawal, cranial electrostimulation therapy and, 116
Tone stimuli
auditory ERPs to, PTSD and, 1006
Tourette's syndrome
basal ganglia volume in trichotillomania and, 39
neuroreceptor subunit genes and, 941
Trail Making Test
schizophrenia and, 797
Transcranial magnetic stimulation
behavioral and biochemical effects, 920
Transporter gene polymorphism
serotonin, schizophrenia and, 634
Treatment refractoriness
heterogeneity of serotonergic response in schizophrenia and, 6
zinc serum level in major depression and, 349
Trichotillomania
basal ganglia volumes in, morphometric MRI and, 39
Tricyclic antidepressants
desipramine in immediate early gene expression and, 317
major depression and cardiac autonomic control, 914
panic disorder and, 982
Tridimensional Personality Questionnaire
clomipramine challenge and, 1124
harm avoidance and, 959
reward dependence and monoamines, 275
Trinucleotide repeat
bipolar disorder and, 876, 1115
schizophrenia and, 756, 760
Tryptophan
acute depletion, lithium-remitted mania and, 1076
metabolism, ECT in depression and, 201
plasma level, prolactin response to fenfluramine and, 416
Tuberoinfundibular dopamine system
alpha-methyl-para-tyrosine and cocaine challenge, 181
β-Tubulin
class III, cerebellum in schizophrenia and, 213
Tumor necrosis factor (TNF)
obsessive-compulsive disorder and, 976
Tyrosine hydroxylase inhibitor
alpha-methyl-para-tyrosine and cocaine challenge, 181

Ubiquitin staining
postmortem, Lewy body variant of Alzheimer's disease and, 527-corr
Unipolar depression
affective disorders and catechol-*o*-methyltransferase, 282
gray matter volume in, 79
University of Pennsylvania Smell Identification Test
gender differences in schizophrenia and, 104
Up-regulation
G protein density in major depression and, 704

Urine
cotinine levels in schizophrenic smokers and, 1
cranial electrostimulation therapy in smoking cessation and, 116
reward dependence and monoamines, 275

Vagal tone
major depression and cardiac autonomic control, 914
Valine
in vitro ^{1}H-magnetic resonance spectroscopy in schizophrenia and, 359
Valproate
clozapine-induced EEG changes and, 132
Vanillomandelic acid
reward dependence and monoamines, 275
Vascular dementia
subcortical hyperintensities in major depression and, 367
Ventral brain systems
gender differences in schizophrenia and, 104
Ventricle-to-brain ratio
structural brain abnormalities in schizophrenia and, 1079
Verbal ability
gender differences in schizophrenia and, 104
Verbal auditory stimuli
event-related potentials in OCD and, 46
Verbal memory
schizophrenia and, 585
Vietnam veterans
posttraumatic stress disorder and, 1006
Violence
PET of murderers and, 495
serotonin and conduct disorder in adolescents, 553
SPECT study in psychopaths and, 96
Visual event-related potentials
chronic cocaine dependence and, 472
Visual go/no go reaction time paradigm
neuroleptic correlates of response production and, 57
Vital capacity parameters
CCK-4 effects on respiratory resistance and, 206
Volume
anterior medial temporallobe, schizophrenia and, 767
lymphocyte, polydipsia-hyponatremia in schizophrenia and, 733
Volumetry
auditory evoked magnetic fields in left hemisphere in schizophrenia and, 609

Wakefulness
REM sleep disinhibition at sleep onset and, 713
White blood cells
apolipoprotein E polymorphism in a population sample age 75 +, 898
White matter
auditory evoked magnetic fields in left hemisphere in schizophrenia, 609
gray matter volume and depression severity, 79
repeat ^{1}H-MRS in social phobia and, 419
subcortical hyperintensities in major depression and, 367
Winter depression
growth hormone response to sumatriptan and, 24
melatonin suppression and, 509
seasonal variation in core temperature regulation during sleep in, 122
Wisconsin Card Sorting Test
schizophrenia and, 104, 797, 816
Withdrawal
alcohol, lactate-induced panic attacks and, 992
cocaine, reduced blue cone electroretinogram and, 631
tobacco, cranial electrostimulation therapy and, 116

Yoga
P300 amplitude after treatment for dysthymia and, 740

zif268
desipramine in immediate early gene expression and, 317
Zinc
serum level, major depression and, 349